

2027 Priority Health Medicare Prior Authorization Criteria

An alphabetical index by drug name appears after the drug criteria listings.

Last updated: September 2026
ID: 27271, Version 12

ACTHAR

Products Affected

- ACTHAR
- ACTHAR GEL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of prior therapies and responses to treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 weeks
Other Criteria	Not covered for acute gouty arthritis, severe psoriasis, and atopic dermatitis. For all covered indications, except infantile spasms, must have a therapeutic trial of a parenteral glucocorticoid AND Cortrophin. Supporting documentation for all drug trials is required demonstrating inadequate response, intolerance, or FDA labeled contraindication to therapy. Reauthorization of previously authorized therapy requires demonstrated clinical benefit. Quantity limited to dosage as supported by the FDA-approved label.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ACTIMMUNE

Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Patient's body surface area (BSA)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ADEMPAS

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	FOR PULMONARY ARTERIAL HYPERTENSION (PAH): Documentation that the patient has pulmonary arterial hypertension (WHO Group 1) confirmed by right heart catheterization must be provided. FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH): Documentation that the patient has CTEPH (WHO Group 4) - and - CTEPH is classified as inoperable or as persistent/recurrent after pulmonary endarterectomy must be provided.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIMOVIG

Products Affected

- AIMOVIG

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other CGRP antagonist therapy.
Required Medical Information	For migraine prevention initial requests: Must have at least four migraine days per month.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial: 1 year. Reauth: 2 years. Dosing must align with FDA labeling.
Other Criteria	For migraine prevention reauthorization requests: Must provide documentation of a decrease in migraine days per month with use of Aimovig.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AKEEGA

Products Affected

- AKEEGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ALECENSA

Products Affected

- ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ALPRAZOLAM

Products Affected

- *alprazolam oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	End of plan year.
Other Criteria	For all indications, approve if: (1) The provider has determined that taking opioids and benzodiazepines together is medically necessary for the patient, OR (2) the patient is in hospice, palliative (end-of-life) care, has cancer and/or has sickle cell disease, OR (3) the patient will not be taking an opioid or benzodiazepine concurrently, OR (4) the patient is less than 18 years old. Note: The criteria only apply to patients 18 years of age or older with concurrent use of a benzodiazepine and opioid. The use of opioids concurrently with benzodiazepines is associated with an increased risk of opioid overdose.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ALUNBRIG

Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ambrisentan

Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Confirmed diagnosis of Pulmonary Arterial Hypertension (PAH), World Health Organization Group 1 by right heart catheterization and medical record documentation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AMITRIPTYLINE

Products Affected

- *amitriptyline hcl oral*

PA Criteria	Criteria Details
Exclusion Criteria	The criteria only apply to patients 65 years and older.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	Coverage requires the following: (1) Prescriber acknowledges that the benefit of therapy outweighs the potential risks for this patient, and (2) Prescriber has considered therapy changes if the patient is using more than one anticholinergic drug in combination. Note: Due to safety concerns, this medication is considered potentially inappropriate in older adults, and is best avoided, prescribed at lower dose, or used with caution.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

aprepitant

Products Affected

- *aprepitant*

PA Criteria	Criteria Details
Exclusion Criteria	Aprepitant is not covered in the following situations: (1) treatment of established nausea and vomiting, and (2) for chronic continuous use.
Required Medical Information	For post-op nausea/vomiting: Provide date of surgery.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Plan year authorization with limit of one 30-day fill for post-op nausea/vomiting
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ARCALYST

Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For the treatment of recurrent pericarditis: Must have documentation supporting a trial and failure (defined as inadequate response) with an NSAID in combination with colchicine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ARIKAYCE

Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For initial review, sputum culture supporting the diagnosis of Mycobacterium avium complex (MAC) lung disease must be submitted.
Age Restrictions	
Prescriber Restrictions	Must be prescribed by or in consultation with an infectious disease specialist or pulmonologist.
Coverage Duration	Initial approval for 6 months. Reauthorization for 12 months.
Other Criteria	For initial review, documentation of failure to obtain negative sputum cultures after a minimum of 6 months of a multidrug background regimen therapy for MAC lung disease must be provided. For reauthorization, documentation of a negative sputum culture obtained within the last 30 days must be provided. Criteria will be applied consistent with current ATS/IDSA guidelines.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

aripiprazole odt

Products Affected

- *aripiprazole oral tablet dispersible*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation to support an inability to use generic aripiprazole tablet.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ARIPIPRAZOLE ORAL SOLUTION

Products Affected

- *aripiprazole oral solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Patient must have tried and have a documented intolerance or contraindication to aripiprazole TABLET and either olanzapine ODT or risperidone ODT.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

armodafinil

Products Affected

- *armodafinil*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

asenapine

Products Affected

- *asenapine maleate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as an inadequate response) with two of the following generic drugs used for at least 28 days each: aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, or lurasidone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AUGTYRO

Products Affected

- AUGTYRO ORAL CAPSULE 160 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AUSTEDO

Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG PACK 12 & 18 & 24 & 30 MG
- AUSTEDO XR
- AUSTEDO XR PATIENT TITRATION ORAL TABLET EXTENDED RELEASE THERAPY

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with tetrabenazine or Ingrezza.
Required Medical Information	TARDIVE DYSKINESIA (TD) INITIAL REQUESTS: (1) Patient has tried and failed tetrabenazine, and (2) the TD is not associated with a dopamine receptor blocking drug, OR (3) the TD is associated with a dopamine receptor blocking drug and symptoms have persisted despite stopping or reducing the dose of the dopamine blocking drug, OR (4) stopping or reducing the dose of the dopamine blocking drug is not possible.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial and reauth: One year.
Other Criteria	REAUTHORIZATION OF TD OR CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE: Documentation supporting improvement or stabilization of the condition with the use of Austedo compared to baseline has been provided.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AUVELITY

Products Affected

- AUVELITY
- AUVELITY TITRATION PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of prior therapies and responses to treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years. Dosing must follow the FDA-approved labeling.
Other Criteria	Must try and fail (defined as an inability to improve depressive symptoms after at least 4 weeks of treatment) with an SSRI or SNRI and 1 atypical antidepressant (e.g., bupropion, mirtazapine).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AVMAPKI-FAKZYNJA

Products Affected

- AVMAPKI FAKZYNJA CO-PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AVONEX

Products Affected

- AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT
- AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AVTOZMA

Products Affected

- AVTOZMA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must align with FDA label or Part D compendia.
Other Criteria	FOR RHEUMATOID ARTHRITIS and JUVENILE IDIOPATHIC ARTHRITIS: Trial of two of the following with inadequate response: a preferred adalimumab product, Rinvoq, tofacitinib or Enbrel. FOR SScILD INITIAL COVERAGE: Confirmed diagnosis by HRCT. FOR SScILD REAUTHORIZATION: Documentation of improvement in condition.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AYVAKIT

Products Affected

- AYVAKIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

BALVERSA

Products Affected

- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

BENLYSTA

Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used with another biologic drug or Lupkynis.
Required Medical Information	For SLE initial requests: Must have a SELENA-SLEDAI score of 6 or more before starting Benlysta AND either an anti-dsDNA antibody greater than 30 IU/ml or ANA greater than 1:80. For LN initial requests: Must have a confirmed diagnosis of SLE AND a kidney biopsy confirming class 3, 4, and/or 5 disease.
Age Restrictions	
Prescriber Restrictions	Prescriber must be a specialist in treating the condition or have consulted with a specialist.
Coverage Duration	1 year initial. 2 years reauthorization.
Other Criteria	For SLE initial requests: Must be taking two of the following drugs together for at least 12 weeks each: a steroid, immunosuppressant, and/or hydroxychloroquine - AND - For SLE reauthorization: Must have evidence of clinical improvement with Benlysta. For lupus nephritis (LN) initial requests: Must be receiving standard therapy for LN (e.g., mycophenolate or azathioprine plus a steroid) - AND - For LN reauthorization: Must have evidence of clinical improvement with Benlysta, including improved or stable eGFR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BESREMI

Products Affected

- BESREMI
- BESREMI PEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years. Dosing must follow the FDA-approved labeling.
Other Criteria	Must trial and fail hydroxyurea (defined as an intolerance and/or persistence or recurrence of disease).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BETASERON

Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

bexarotene

Products Affected

- *bexarotene oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

BEXAROTENE GEL

Products Affected

- *bexarotene external*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Must first try tazarotene.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BILPREVDA

Products Affected

- BILPREVDA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

bosentan

Products Affected

- *bosentan oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Confirmed diagnosis of Pulmonary Arterial Hypertension (PAH), World Health Organization Group 1 by right heart catheterization and medical record documentation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

BOSULIF

Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

BOSUTINIB

Products Affected

- *bosutinib oral tablet 100 mg, 400 mg, 500 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

BRAFTOVI

Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Patient must have documentation of BRAF V600 mutation status.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

BRIVARACETAM

Products Affected

- *brivaracetam oral solution*
- *brivaracetam oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as inadequate seizure control) with generic levetiracetam and at least 1 other generic anticonvulsant for the condition.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BRUKINSA

Products Affected

- BRUKINSA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	For CLL/SLL, marginal zone lymphoma, mantle cell lymphoma, and Waldenström Macroglobulinemia where NCCN Guidelines give the same category of recommendation: Your prescriber must provide rationale supporting why Calquence or Imbruvica cannot be used in place of Brukinsa.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

BYSANTI

Products Affected

- BYSANTI
- BYSANTI TITRATION PACK A
- BYSANTI TITRATION PACK B
- BYSANTI TITRATION PACK C

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Must have documentation supporting a trial and failure (defined as an inadequate response) with two of the following generic drugs that have support for the requested condition and each used for at least 28 days: aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, or lurasidone.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CABOMETYX

Products Affected

- CABOMETYX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

calcipotriene/betamethasone suspension

Products Affected

- *calcipotriene-betameth diprop external suspension*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure with a generic topical steroid for the scalp (such as fluocinonide solution, clobetasol solution, clobetasol shampoo) in combination with generic calcipotriene solution. Failure is defined as an inadequate response in treating the condition.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CALQUENCE

Products Affected

- CALQUENCE ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CAPLYTA

Products Affected

- CAPLYTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of prior therapies and responses to treatment must be provided.
Age Restrictions	Must be age 18 or older.
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	For schizophrenia: Patient must have tried and failed (defined as taking the medication as prescribed without an adequate response or with intolerance) two of the following generic atypical antipsychotics: aripiprazole, ziprasidone, olanzapine, risperidone, quetiapine. For depressive episodes associated with bipolar 1 disorder: Patient must have tried and failed (defined above) one of the following generic products: quetiapine or olanzapine (with fluoxetine) - AND - Patient must have tried and failed (defined above) generic lurasidone. For depressive episodes associated with bipolar 2 disorder: Patient must have tried and failed (defined above) quetiapine. For adjunctive therapy with antidepressants for major depressive disorder (MDD): Must have tried and failed (defined above) two generic atypical antipsychotics (such as aripiprazole and quetiapine ER).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

CAPRELSA

Products Affected

- CAPRELSA ORAL TABLET 100 MG, 300 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CARGLUMIC ACID

Products Affected

- *carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CAVHANZA

Products Affected

- CAVHANZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis, prior therapies.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Must have a documented inability to use generic nilotinib.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CAYSTON

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CHLORDIAZEPOXIDE

Products Affected

- *chlordiazepoxide hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	End of plan year.
Other Criteria	For all indications, approve if: (1) The provider has determined that taking opioids and benzodiazepines together is medically necessary for the patient, OR (2) the patient is in hospice, palliative (end-of-life) care, has cancer and/or has sickle cell disease, OR (3) the patient will not be taking an opioid or benzodiazepine concurrently, OR (4) the patient is less than 18 years old. Note: The criteria only apply to patients 18 years of age or older with concurrent use of a benzodiazepine and opioid. The use of opioids concurrently with benzodiazepines is associated with an increased risk of opioid overdose.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

clobazam

Products Affected

- *clobazam oral suspension 2.5 mg/ml*
- *clobazam oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Patient must first try one generic anticonvulsant. Clobazam suspension may only be used in patients where tablets are contraindicated (e.g., dysphagia).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CLONAZEPAM

Products Affected

- *clonazepam oral tablet 0.5 mg, 1 mg, 2 mg*
- *clonazepam oral tablet dispersible 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	End of plan year.
Other Criteria	For all indications, approve if: (1) The provider has determined that taking opioids and benzodiazepines together is medically necessary for the patient, OR (2) the patient is in hospice, palliative (end-of-life) care, has cancer and/or has sickle cell disease, OR (3) the patient will not be taking an opioid or benzodiazepine concurrently, OR (4) the patient is less than 18 years old. Note: The criteria only apply to patients 18 years of age or older with concurrent use of a benzodiazepine and opioid. The use of opioids concurrently with benzodiazepines is associated with an increased risk of opioid overdose.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CLORAZEPATE DIPOTASSIUM

Products Affected

- *clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	End of plan year.
Other Criteria	For all indications, approve if: (1) The provider has determined that taking opioids and benzodiazepines together is medically necessary for the patient, OR (2) the patient is in hospice, palliative (end-of-life) care, has cancer and/or has sickle cell disease, OR (3) the patient will not be taking an opioid or benzodiazepine concurrently, OR (4) the patient is less than 18 years old. Note: The criteria only apply to patients 18 years of age or older with concurrent use of a benzodiazepine and opioid. The use of opioids concurrently with benzodiazepines is associated with an increased risk of opioid overdose.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CLOZAPINE ODT

Products Affected

- *clozapine oral tablet dispersible*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The patient has had prior trial AND a documented contraindication (e.g. dysphagia) to generic clozapine tablet.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

COBENFY

Products Affected

- COBENFY
- COBENFY STARTER PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as an inadequate response) with two generic atypical antipsychotics used for at least 28 days each.
Age Restrictions	Must be age 18 or older.
Prescriber Restrictions	Must be prescribed by, or in consultation with, a specialist for the condition being treated.
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

COMETRIQ

Products Affected

- COMETRIQ (100 MG DAILY DOSE) ORAL
KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL
KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

COPIKTRA

Products Affected

- COPIKTRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CORTROPHIN

Products Affected

- CORTROPHIN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial-in accordance with FDA label or max of 3 mos. if unspecified in label. Reauth-1 year.
Other Criteria	For acute exacerbations of multiple sclerosis: trial of a parenteral and an oral glucocorticoid. For nephrotic syndrome associated with lupus erythematosus, systemic lupus erythematosus, and inflammatory ocular disorders: trial of a parenteral glucocorticoid and an immunosuppressant (e.g. cyclophosphamide, tacrolimus, mycophenolate mofetil, methotrexate, azathioprine). For adjunctive therapy for short-term administration in rheumatic disease: trial of a parenteral glucocorticoid and a covered biologic drug. For systemic dermatomyositis (polymyositis): trial of a parenteral glucocorticoid and rituximab. For all other covered indications, except infantile spasms: trial of a parenteral glucocorticoid and one other medication for the condition. Infantile spasm does not require prerequisite drug trials. Supporting documentation for all drug trials is required demonstrating inadequate response, intolerance, or FDA labeled contraindication to therapy. Reauthorization of previously authorized therapy requires demonstrated clinical benefit. Quantity limited to dosage as supported by the FDA-approved label for all requests.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Infantile Spasms
Part B Prerequisite	Yes

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

COSENTYX

Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	FOR ANKYLOSING SPONDYLITIS and NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NRAS): Trial of an NSAID with inadequate response. FOR PSORIASIS: Trial of a traditional DMARD (e.g., methotrexate, cyclosporine, acitretin) with inadequate response. FOR ERA: Trial of one other drug (e.g., methotrexate, NSAIDs) with inadequate response - or - have aggressive disease that requires initial biologic therapy. FOR HIDRADENITIS SUPPURATIVA: Trial of one other therapy (e.g., prednisone, clindamycin) with inadequate response.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

COTELLIC

Products Affected

- COTELLIC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CRESEMBA

Products Affected

- CRESEMBA ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	For invasive aspergillosis, documentation to support an inability to use generic voriconazole for the condition must be provided.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CYSTADROPS

Products Affected

- CYSTADROPS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CYSTARAN

Products Affected

- CYSTARAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

DALFAMPRIDINE ER

Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
Exclusion Criteria	Not covered with any of the following: (1) History of seizure, (2) Creatinine clearance (CrCl) of 50 ml per min or less, and (3) Patient is wheel-chair bound.
Required Medical Information	INITIAL: CrCl, diagnosis, walking status, baseline T25FW. REAUTH: CrCl, walking status, T25FW or other objective measurement.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial and Reauthorization: 1 year
Other Criteria	INITIAL COVERAGE: Requires documentation of a baseline timed 25-foot walk (T25FW) test (prior to initiation of dalfampridine treatment). REAUTHORIZATION: Requires documentation of stability or improvement in the T25FW test or in another objective measure of walking ability compared to baseline (prior to treatment with dalfampridine).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

DANZITEN

Products Affected

- DANZITEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

DASATINIB

Products Affected

- *dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

DAURISMO

Products Affected

- DAURISMO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Diabetic Supplies

Products Affected

- *assure id insulin safety syr 29g x 1/2" 1 ml*
- *bd autoshield duo*
- *bd pen needle 29g x 12mm*
- *bd pen needle micro ulf*
- *bd pen needle micro ultrafine*
- *bd pen needle mini ulf*
- *bd pen needle mini ultrafine*
- *bd pen needle nano 2nd gen*
- *bd pen needle nano ulf*
- *bd pen needle nano ultrafine*
- *bd pen needle orig ultrafine*
- *bd pen needle original ulf*
- *bd pen needle short ulf*
- *bd pen needle short ultrafine*
- *comfort assist insulin syringe 29g x 1/2" 1 ml*
- *cvs gauze sterile pad 2"x2"*
- *embecta autoshield duo*
- *embecta pen needle nano*
- *embecta pen needle nano 2 gen*
- *embecta pen needle ultrafine*
- *global alcohol prep ease*
- *novofine pen needle*
- *novofine plus pen needle*
- *preferred plus insulin syringe 28g x 1/2" 0.5 ml*
- *reli-on insulin syringe 29g 0.3 ml*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

DIACOMIT

Products Affected

- DIACOMIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(1) Patient has a diagnosis of seizures associated with Dravet syndrome AND (2) Patient is not currently controlled on current therapy (defined as experiencing generalized tonic clonic or clonic seizures within the past 28 days) AND (3) Patient taking concomitant clobazam therapy.
Age Restrictions	
Prescriber Restrictions	Must be prescribed by or in consultation with a specialist (i.e. neurologist, epileptologist).
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DIAZEPAM

Products Affected

- DIAZEPAM INTENSOL
- *diazepam oral solution 5 mg/5ml*
- *diazepam oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	End of plan year.
Other Criteria	For all indications, approve if: (1) The provider has determined that taking opioids and benzodiazepines together is medically necessary for the patient, OR (2) the patient is in hospice, palliative (end-of-life) care, has cancer and/or has sickle cell disease, OR (3) the patient will not be taking an opioid or benzodiazepine concurrently, OR (4) the patient is less than 18 years old. Note: The criteria only apply to patients 18 years of age or older with concurrent use of a benzodiazepine and opioid. The use of opioids concurrently with benzodiazepines is associated with an increased risk of opioid overdose.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

DICHLORPHENAMIDE

Products Affected

- *dichlorphenamide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

dihydroergotamine nasal spray

Products Affected

- *dihydroergotamine mesylate nasal*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation to support (1) a trial and failure (defined as inability to improve symptoms or condition) of one non-oral triptan drug (e.g., sumatriptan nasal spray or injection) AND (2) a trial and failure (defined above) of Nurtec ODT.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

dimethyl fumarate

Products Affected

- *dimethyl fumarate oral*
- *dimethyl fumarate starter pack oral capsule*
delayed release therapy pack

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

DRIZALMA

Products Affected

- DRIZALMA SPRINKLE ORAL CAPSULE
DELAYED RELEASE SPRINKLE 20 MG, 30
MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have current documentation to support the following: (1) an inability to use duloxetine (generic Cymbalta), and (2) trial and failure (defined as an inability to improve the condition) with one other generic antidepressant.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

droxidopa

Products Affected

- *droxidopa*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year initial and reauthorization.
Other Criteria	Patient must first try midodrine. For reauthorization: Must have documentation of a positive clinical response (e.g., sustained decrease in dizziness).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DUPIXENT

Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/1.14ML, 300 MG/2ML
- DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 200 MG/1.14ML, 300 MG/2ML
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML, 300 MG/2ML

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis, concurrent therapies (CRSwNP), and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	1 year initial, 2 years reauth. Dose must align with FDA label or Part D compendia.

PA Criteria	Criteria Details
Other Criteria	ASTHMA INITIAL COVERAGE: (1) Use of an ICS/LABA inhaler as prescribed in the past 6 months with inadequate control of condition, AND (2) Current dependence on oral steroids OR a blood eosinophil level at least 150 cells per microliter in the past 12 months. EOSINOPHILIC ESOPHAGITIS (EOE) INITIAL COVERAGE: (1) confirmed diagnosis by biopsy defined as 15 or more eosinophils per high power field (HPF), and (2) symptomatic disease, and (3) Current weight at least 15 kg, AND (4) trial of a proton pump inhibitor or a swallowed topical steroid (e.g., fluticasone, budesonide) for at least 2 months with inadequate response. PRURIGO NODULARIS (PN) INITIAL COVERAGE: Confirmed diagnosis. ATOPIC DERMATITIS (AD) INITIAL COVERAGE: (1) Moderate to severe disease, AND (2) Trial of a medium or higher potency topical steroid or topical calcineurin inhibitor with inadequate response. CHRONIC RHINOSINUSITIS WITH NASAL POLYP (CRSwNP) INITIAL COVERAGE: (1) Chronic disease defined as 2 or more of the following symptoms for at least 12 weeks despite management (e.g., intranasal steroids, etc.): nasal congestion, obstruction, or blockage, nasal drainage, facial pain/pressure, or reduction in smell, AND (2) trial of an intranasal steroid with inadequate response, AND (3) Concurrent use of Dupixent and an intranasal steroid. COPD INITIAL COVERAGE: (1) blood eosinophil level at least 300 cells per microliter within the past 12 months, AND (2) Trial and failure of a LAMA, LABA, and ICS inhaled regimen used together (also called triple therapy) and as prescribed with failure defined as 2 or more COPD exacerbations in the past 12 months or 1 COPD hospitalization in the past 12 months. CHRONIC URTICARIA (CU) INITIAL COVERAGE: (1) Urticaria occurring for more than 6 weeks, and (2) trial of an H1 antihistamine with inadequate response. BULLOUS PEMPHIGOID (BP) INITIAL COVERAGE: (1) Confirmed diagnosis, AND (2) trial of a generic steroid-sparing drug (such as doxycycline, methotrexate, etc.) with inadequate response. ALLERGIC FUNGAL RHINOSINUSITIS (AFRS) INITIAL COVERAGE: Confirmed diagnosis and history of sino-nasal surgery. REAUTHORIZATION FOR ALL INDICATIONS: Documentation of clinical benefit compared to baseline (prior to Dupixent) - and - for CRSwNP only - continued use of Dupixent with an intranasal steroid.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ELTROMBOPAG

Products Affected

- *eltrombopag olamine oral packet 12.5 mg, 25 mg*
- *eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Use of eltrombopag to normalize platelet counts is not covered.
Required Medical Information	Documentation supporting the request including current platelet count must be provided.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	FOR ITP INITIAL REQUESTS: (1) Must have a platelet count less than 30,000/mcL - OR - less than 50,000/mcL with bleeding or risk factor(s) for bleeding (e.g., history of bleeding, conditions that increase bleeding risk like peptic ulcer disease, history of falling, anticoagulation therapy), AND (2) Must have an inadequate response or intolerance to steroids or immunoglobulins, AND (3) Must have an inadequate response or intolerance to rituximab or splenectomy, AND (4) must not be used in combination with other drugs used for maintenance treatment of ITP including other thrombopoietin receptor agonists (ex: Doptelet, Nplate), Wayrilz, or Tavilisse. FOR THROMBOCYTOPENIA FROM HEPATITIS C INITIAL REQUESTS: Degree of thrombocytopenia prevents the initiation OR maintenance of interferon-based therapy. FOR APLASTIC ANEMIA INITIAL REQUESTS: Must be used with standard immunosuppressive therapy (antithymocyte globulin and cyclosporine) for first-line treatment or must have had an insufficient response to cyclosporine for second-line or subsequent treatment. FOR REAUTHORIZATION OF ALL PREVIOUSLY APPROVED REQUESTS: (1) Documentation that current platelet count is less than 400 x 10 ⁹ /L, AND (2) Documentation that supports patient is positively responding to therapy.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	Yes
Prerequisite Therapy Required	Yes

EMGALITY

Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other CGRP antagonist therapy.
Required Medical Information	FOR MIGRAINE PREVENTION INITIAL REQUESTS: Must have at least four migraine days per month. FOR CLUSTER HEADACHE INITIAL REQUESTS: Must try verapamil and have an intolerance or inability to improve the condition.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year. Cluster reauth: 1 year. Migraine reauth: 2 years. Dosing must align with FDA labeling.
Other Criteria	For migraine prevention reauthorization requests: Must provide documentation of a decrease in migraine days per month with use of Emgality. For cluster headache reauthorization requests: Must provide documentation of a decrease in the frequency or intensity of cluster headaches with Emgality.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EMSAM

Products Affected

- EMSAM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation supporting the trial and failure (defined as an inadequate improvement in depressive symptoms) with two of the following generic antidepressants is required: SNRIs, SSRIs, mirtazapine, or bupropion.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ENBREL

Products Affected

- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML, 50 MG/ML
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	Must try and fail adalimumab. Fail is defined as an intolerance or inability to improve condition.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ENBREL MINI

Products Affected

- ENBREL MINI

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	Must try and fail adalimumab. Fail is defined as an intolerance or inability to improve condition.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ENSACOVE

Products Affected

- ENSACOVE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ENTYVIO PEN

Products Affected

- ENTYVIO PEN

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	FOR CROHN'S DISEASE: (1) Patient has tried two of the following: infliximab, adalimumab, ustekinumab, Skyrizi, and Rinvoq. FOR ULCERATIVE COLITIS: (1) Patient has tried two of the following: infliximab, adalimumab, ustekinumab, tofacitinib, Skyrizi, and Rinvoq.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EPIDIOLEX

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure with at least 2 generic anticonvulsants for the condition.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ERIVEDGE

Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ERLEADA

Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	FOR METASTATIC DISEASE: Patient must be unable to use (such as a failure, intolerance or contraindication to) abiraterone and Xtandi. FOR NON-METASTATIC DISEASE: Patient must be unable to use (such as a failure, intolerance or contraindication to) Xtandi.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

erlotinib

Products Affected

- *erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ESLICARBAZEPINE

Products Affected

- *eslicarbazepine acetate oral tablet 200 mg, 400 mg, 600 mg, 800 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as inadequate seizure control) with at least 2 generic anticonvulsants for the condition.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EUCRISA

Products Affected

- EUCRISA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Approve in patients who have tried and failed a prescription strength topical steroid for the current condition being treated. If a topical steroid is not appropriate for the patient, approve in patients who have tried a generic topical calcineurin inhibitor for the current condition being treated.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EULEXIN

Products Affected

- EULEXIN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	Coverage requires a trial with generic flutamide or bicalutamide.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

everolimus

Products Affected

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

EXXUA ER

Products Affected

- EXXUA
- EXXUA TITRATION PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of prior therapies and responses to treatment must be provided.
Age Restrictions	Must be age 18 or older.
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	For the treatment of major depressive disorder (MDD), must try and fail (defined as an inability to improve depressive symptoms after at least 4 weeks of treatment) with two generic antidepressants from a different class, one of which must be either bupropion or mirtazapine.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FANAPT

Products Affected

- FANAPT TABLET
- FANAPT TITRATION PACK A
- FANAPT TITRATION PACK B ORAL TABLET
- FANAPT TITRATION PACK C ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as an inadequate response) with two of the following generic drugs that have support for the requested condition and each used for at least 28 days: aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, or lurasidone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FARXIGA

Products Affected

- FARXIGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	Must have documentation that supports an inability to use generic dapagliflozin.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FASENRA

Products Affected

- FASENRA PEN
- FASENRA SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 10 MG/0.5ML, 30
 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs.
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	1 year initial, 2 years reauth. Dose must align with FDA label or Part D compendia.
Other Criteria	ASTHMA INITIAL COVERAGE: (1) Use of an ICS/LABA inhaler as prescribed in the past 6 months with inadequate control of condition, AND (2) blood eosinophil level at least 150 cells per microliter in the past 12 months. FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) INITIAL COVERAGE: (1) Non-severe EGPA (defined as absence of life or organ-threatening manifestations). REAUTHORIZATION FOR ALL INDICATIONS: Documentation of clinical benefit compared to baseline (prior to Fasenra.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FILSPARI

Products Affected

- FILSPARI ORAL TABLET 200 MG, 400 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis, kidney biopsy report, proteinuria measure (g/day or g/24 hours), history of prior therapies, clinical benefit (for reauthorization)
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with a specialist.
Coverage Duration	One year initial and reauthorization.
Other Criteria	FOR IgA NEPHROPATHY INITIAL COVERAGE: (1) Patient has primary IgA nephropathy confirmed by biopsy, AND (2) Patient has persistent proteinuria (defined as 0.5 grams/day or more) despite use of a maximally tolerated ACEI or ARB, AND (3) Patient is not receiving dialysis, AND (4) Patient has not undergone kidney transplant. FOR IgA NEPHROPATHY REAUTHORIZATION: Patient has experienced clinical benefit evidenced by a reduction in proteinuria. FOR FSGS INITIAL COVERAGE: (1) Patient has primary focal segmental glomerulosclerosis (FSGS) confirmed by biopsy, AND (2) Patient is not currently in nephrotic syndrome (defined as proteinuria greater than 3.5 grams per 24 hours in adults), AND (3) Patient has persistent proteinuria (defined as 0.5 grams/day or more) despite use of a maximally tolerated ACEI or ARB, AND (4) Patient is not receiving dialysis, AND (5) Patient has not undergone kidney transplant. FOR FSGS REAUTHORIZATION: (1) Patient has experienced clinical benefit evidenced by a reduction in proteinuria, and (2) Patient is not currently in NS (defined as proteinuria greater than 3.5 grams per 24 hours in adults).
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FINGOLIMOD

Products Affected

- *fingolimod hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

FINTEPLA

Products Affected

- FINTEPLA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as inadequate seizure control) with two of the following: clobazam, valproic acid, topiramate.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FOTIVDA

Products Affected

- FOTIVDA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

FRUZAQLA

Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

GAVRETO

Products Affected

- GAVRETO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

GEFITINIB

Products Affected

- *gefitinib*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

GILOTRIF

Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

glatiramer

Products Affected

- *glatiramer acetate subcutaneous solution
prefilled syringe 20 mg/ml, 40 mg/ml*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

GLATOPA

Products Affected

- GLATOPA SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE 20 MG/ML, 40
MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

GOMEKLI

Products Affected

- GOMEKLI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

GROWTH HORMONE

Products Affected

- NORDITROPIN FLEXPRO
SUBCUTANEOUS SOLUTION PEN-
INJECTOR 10 MG/1.5ML, 15 MG/1.5ML, 5
MG/1.5ML
- OMNITROPE SUBCUTANEOUS
SOLUTION CARTRIDGE
- OMNITROPE SUBCUTANEOUS
SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	FOR CHILDREN: must submit an untreated growth velocity curve with a minimum of 1 year of growth data showing a growth velocity of less than 10th % for bone age and gender, growth plates must be open, bone age must be a minimum of 1 year behind chronological age (unless GHD is related to pituitary surgery, radiation therapy, or with precocious puberty), must have a documented GH deficiency via 2 growth hormone stimulation tests below 10ng/ml or GH stimulation test level less than 15 ng/ml + IGF-1 and IGF-PB3 levels below normal for bone age and sex, decreased muscle tone by exam. FOR ADULTS with a diagnosis of GHD: Must have confirmation of GHD by meeting one of the following: (1) A suboptimal response using an appropriate GH-stimulation test, (2) Child-onset GHD with confirmed persistent GHD, or (3) patient has all the following: (a) documented pituitary or hypothalamic disease (e.g., brain tumor with previous brain irradiation), (b) greater than or equal to 3 pituitary hormone deficiencies (thyroid-stimulating hormone (TSH), corticotropin (ACTH), and gonadotropins), and (c) low insulin-like growth factor-1 (IGF-1). If IGF-1 value is indeterminate, a suboptimal response on an appropriate GH-stimulation test required.
Age Restrictions	
Prescriber Restrictions	Must be prescribed by an endocrinologist, gastroenterologist, or nephrologist.
Coverage Duration	One year

PA Criteria	Criteria Details
Other Criteria	FOR CHILDREN: Diagnosis of Growth Hormone Deficiency-height must be less than the 5th% fir age/sex. Diagnosis of Turner's syndrome-height must be less than 10th%. Diagnosis of Pre-transplant chronic renal insufficiency-height must be less than 5th% for age/sex and patient must be receiving weekly dialysis or SCR less than 2 mg/dL. FOR CHILDREN: must not have constitutional growth delay, or acute or chronic catabolic illness. FOR ADULTS, the following conditions are not covered: treatment of reduced growth hormone related to aging, Turner's syndrome or cystinosis. For reauthorization in adults and children: Above normal IGF-1 level requires provider attestation that dose will be decreased and therapy will be managed to obtain a level within normal range.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

HADLIMA

Products Affected

- HADLIMA PUSHTOUCH SUBCUTANEOUS SOLUTION AUTO-INJECTOR 40 MG/0.4ML, 40 MG/0.8ML
- HADLIMA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML, 40

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	FOR RHEUMATOID ARTHRITIS: Trial of a traditional DMARD (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) with inadequate response. FOR PSORIASIS: Trial of a traditional DMARD (e.g., methotrexate, cyclosporine, acitretin) with inadequate response. FOR ANKYLOSING SPONDYLITIS: Trial of an NSAID with inadequate response. FOR HIDRADENITIS SUPPURATIVA: Trial of one other therapy (e.g., prednisone, clindamycin) with inadequate response. FOR UVEITIS: Trial of one other therapy (e.g., intraocular or oral steroid) with inadequate response. FOR JUVENILE IDIOPATHIC ARTHRITIS: Trial of one other therapy (e.g., methotrexate, NSAIDs) with inadequate response - or - patient is starting the drug concurrently with methotrexate, sulfasalazine, or leflunomide - or - the patient has aggressive disease, as determined by the physician.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Haegarda

Products Affected

- HAEGARDA

PA Criteria	Criteria Details
Exclusion Criteria	Haegarda is not covered if any of the following are met: (1) use in combination with an angiotensin-converting enzyme inhibitor (ACEI), (2) use in combination with other preventative therapies for HAE (e.g., Orladeyo, Takhyzo), and/or (3) used for the treatment of acute attacks.
Required Medical Information	Requires submission of C4, C1-INH protein, and C1-INH function lab results confirming diagnosis.
Age Restrictions	Must be age 6 or older.
Prescriber Restrictions	Prescriber is an allergist, immunologist, hematologist, or other specialist experienced in treating HAE.
Coverage Duration	1 year initial and reauth
Other Criteria	For reauthorization: Must also have documentation showing a decrease in the frequency of attacks.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

HERNEXEOS

Products Affected

- HERNEXEOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

HYRNUO

Products Affected

- HYRNUO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

IBRANCE

Products Affected

- IBRANCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

IBTROZI

Products Affected

- IBTROZI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

icatibant acetate

Products Affected

- *icatibant acetate subcutaneous solution prefilled syringe*
- SAJAZIR SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of an angiotensin-converting enzyme inhibitor (ACEI) is not covered.
Required Medical Information	Documentation of C4, C1-INH protein, and C1-INH function lab results confirming diagnosis.
Age Restrictions	Must be age 18 or older.
Prescriber Restrictions	Prescriber is an allergist, immunologist, hematologist, or other specialist experienced in treating HAE.
Coverage Duration	6 months, initial and reauthorization.
Other Criteria	For reauthorization: Must have documentation showing use of previously approved syringes AND a favorable clinical response (decrease in the duration of attacks, quick onset of symptom relief, resolution of symptoms, decrease in attack frequency or severity).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ICLUSIG

Products Affected

- ICLUSIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

IDHIFA

Products Affected

- IDHIFA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of IDH2 (isocitrate dehydrogenase-2) mutation must be submitted.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

imatinib mesylate

Products Affected

- *imatinib mesylate oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

IMBRUVICA

Products Affected

- IMBRUVICA ORAL CAPSULE
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years. Dosing must follow the FDA-approved labeling.
Other Criteria	Criteria will be applied consistent with current NCCN guidance. Reauthorization for GVHD: Must have documentation of clinical benefit.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

IMKELDI

Products Affected

- *imkeldi*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Coverage requires that the patient is unable to swallow or appropriately use the generic imatinib tablet formulation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

IMPAVIDO

Products Affected

- IMPAVIDO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One month
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

INCRELEX

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	Increlex is not covered in patients with closed epiphyses.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

INFLIXIMAB

Products Affected

- *infliximab*

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-approved labeling or be supported in approved compendia for Part D.
Other Criteria	FOR RHEUMATOID ARTHRITIS AND PSORIASIS: Trial of a traditional non-biologic DMARD (such as methotrexate) with inadequate response. FOR ANKYLOSING SPONDYLITIS: Trial of an NSAID with inadequate response. FOR HIDRADENITIS SUPPURATIVA AND UVEITIS: Trial of one other therapy for the condition (such as prednisone) with inadequate response. FOR JUVENILE IDIOPATHIC ARTHRITIS: Trial of one other therapy for the condition (such as methotrexate or NSAIDs) with inadequate response - or - patient is starting the drug concurrently with methotrexate, sulfasalazine, or leflunomide - or - the patient has aggressive disease, as determined by the physician.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

INLURIYO

Products Affected

- INLURIYO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

INLYTA

Products Affected

- INLYTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

INQOVI

Products Affected

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Patient must first try IV decitabine.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	Yes
Prerequisite Therapy Required	Yes

INREBIC

Products Affected

- INREBIC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Must have tried and failed (defined as an intolerance or inability to improve the condition) Jakafi.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ISTURISA

Products Affected

- ISTURISA ORAL TABLET 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation supporting an FDA-approved diagnosis of Cushing syndrome in an adult where surgery is not an option or has not been curative.
Age Restrictions	
Prescriber Restrictions	Must be prescribed by an endocrinologist.
Coverage Duration	Two years
Other Criteria	Patient must have tried and failed two of the following: ketoconazole, Lysodren, and cabergoline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ITOVEBI

Products Affected

- ITOVEBI ORAL TABLET 3 MG, 9 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

IVIG

Products Affected

- GAMUNEX-C

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(1) A current weight and requested dose, AND (2) Dosing must follow FDA-approved labeling, or have documentation supporting that the requested dose follows accepted standards of medical practice, AND (3) Patient's dose has been weight-adjusted if the BMI is 30 or more or the actual body weight is 20% higher than the member's ideal body weight, AND (4) Medical records supporting the request, including support for the diagnosis and dose have been provided.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	Diagnosis and administration information will be reviewed to determine if coverage is available as a Medicare Part B or Part D benefit. FOR MYASTHENIA GRAVIS: Patient must be experiencing acute myasthenic crisis with decompensation. Use of IVIG for chronic or routine use is not covered (there is a lack of evidence to support use of IVIG in stable MG).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

IWILFIN

Products Affected

- IWILFIN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

JAKAFI

Products Affected

- JAKAFI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Criteria will be applied consistent with current NCCN guidance. Reauthorization for GVHD: Must have documentation of clinical benefit.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

JARDIANCE

Products Affected

- JARDIANCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	Must have documentation that supports an inability to use generic dapagliflozin.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

JAYPIRCA

Products Affected

- JAYPIRCA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis, prior therapies, NCCN alignment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	Coverage requires: (1) The use of Jaypirca follows current NCCN recommendations, and (2) Patient has been previously treated with Calquence or Imbruvica.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

JYLAMVO

Products Affected

- JYLAMVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Must have current documentation to support an inability to use generic methotrexate. Diagnosis will be reviewed to determine if coverage is available as a Medicare Part B or Part D benefit.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

KALYDECO

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Patient must have laboratory confirmation of ivacaftor-responsive mutation in the CFTR gene.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

KERENDIA

Products Affected

- KERENDIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For initial treatment in adults with heart failure and left ventricular ejection fraction (LVEF) greater than or equal to 40%: (1) Patient has New York Heart Association (NYHA) Class II through IV heart failure, AND (2) Patient has a documented ejection fraction of 40% or more in the previous 12 months, and (3) patient has a pre-treatment eGFR of 25ml/min/1.73m ² or more, and (4) Kerendia has been prescribed by, or in consultation with, a cardiologist, AND (5) Patient has been receiving standard heart failure treatment defined as taking at least 2 of the following medications together, each from a different class, and at appropriate doses for heart failure: ACEI, ARB, or Entresto, bisoprolol, carvedilol or metoprolol ER, and/or a diuretic such as spironolactone or furosemide.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	FOR CHRONIC KIDNEY DISEASE (CKD) ASSOCIATED WITH TYPE 2 DIABETES (T2DM) INITIAL REQUESTS: (1) Must try an SGLT2i or GLP-1 RA initially and provide support through medical records for adding or switching to Kerendia (such as having an intolerance, contraindication, or having regular assessments and monitoring following initial therapy that support additional risk-based therapy per ADA guidelines), and (2) must be on maximally tolerated ACEI or ARB, and (3) must have an eGFR greater than or equal to 25ml/min/1.73m ² .
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

KISQALI

Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

KOMZIFTI

Products Affected

- KOMZIFTI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

KOSELUGO

Products Affected

- KOSELUGO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

KRAZATI

Products Affected

- *krazati*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Medical records supporting that the use of Krazati follows current NCCN recommendations must be provided.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Use of Krazati must follow current NCCN recommendations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

lapatinib

Products Affected

- *lapatinib ditosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LAZCLUZE

Products Affected

- LAZCLUZE ORAL TABLET 240 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LENALIDOMIDE

Products Affected

- *lenalidomide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LENVIMA

Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LEVETIRACETAM ORAL TABLET DISINTEGRATING SOLUBLE

Products Affected

- *levetiracetam oral tablet disintegrating soluble 250 mg, 500 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have current documentation to support the following: (1) an inability to use generic levetiracetam tablet, and (2) trial and failure (defined as an inability to improve the condition) with one other generic anticonvulsant.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

L-Glutamine

Products Affected

- *L-glutamine oral packet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Must try and fail hydroxyurea. Fail is defined as continuing to have pain episodes despite appropriately dosed hydroxyurea or having any intolerance to hydroxyurea.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LIDOCAINE PATCH

Products Affected

- *lidocaine external patch 5 %*
- LIDOCAN
- LIDOCAN III
- TRIDACAINE III
- TRIDACAINE XL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Medically accepted indications for lidocaine 5% patch include relief of pain associated with postherpetic neuralgia (PHN), diabetic neuropathy, and cancer-related neuropathic pain.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LIFYORLI

Products Affected

- LIFYORLI (125 MG DOSE)
- LIFYORLI (150 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LIVTENCITY

Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Baseline CMV DNA level confirming diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	8 weeks
Other Criteria	Must not be used concomitantly with other CMV antivirals (e.g., ganciclovir, valganciclovir). Dosing must follow FDA-approved labeling. Must have documented trial and failure with ganciclovir, valganciclovir, cidofovir or foscarnet. For reauthorization, documentation of response (e.g., CMV DNA level) must be provided.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LONSURF

Products Affected

- LONSURF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LORAZEPAM

Products Affected

- LORAZEPAM INTENSOL
- *lorazepam oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	End of plan year.
Other Criteria	For all indications, approve if: (1) The provider has determined that taking opioids and benzodiazepines together is medically necessary for the patient, OR (2) the patient is in hospice, palliative (end-of-life) care, has cancer and/or has sickle cell disease, OR (3) the patient will not be taking an opioid or benzodiazepine concurrently, OR (4) the patient is less than 18 years old. Note: The criteria only apply to patients 18 years of age or older with concurrent use of a benzodiazepine and opioid. The use of opioids concurrently with benzodiazepines is associated with an increased risk of opioid overdose.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LORBRENA

Products Affected

- LORBRENA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LUMAKRAS

Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LUPRON DEPOT

Products Affected

- LUPRON DEPOT (1-MONTH)
INTRAMUSCULAR KIT 3.75 MG
- LUPRON DEPOT (3-MONTH)
INTRAMUSCULAR KIT 11.25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LYBALVI

Products Affected

- LYBALVI

PA Criteria	Criteria Details
Exclusion Criteria	Not covered for patients currently using opioids. Not covered for patients undergoing acute opioid withdrawal.
Required Medical Information	Documentation of diagnosis, baseline and current weight, and prior therapy trial and failure.
Age Restrictions	Must be 18 years of age or older
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	(1) Patient does not have a known opioid use disorder and is not dependent on opioids for a chronic health condition, and (2) Patient has tried and failed olanzapine, and (3) Patient has tried and failed another generic atypical antipsychotic associated with less weight gain such as aripiprazole or lurasidone. Failure is defined as demonstrating a positive clinical response to the required therapy, but with clinically significant weight gain defined as 7 percent of more weight gain compared to baseline (weight prior to Lybalvi).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LYNPARZA

Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

LYTGOBI

Products Affected

- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

MACITENTAN

Products Affected

- *macitentan*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis, prior therapies.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	FOR PAH (WHO GROUP 1): Diagnosis confirmed by right heart catheterization.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

MARPLAN

Products Affected

- MARPLAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation supporting the trial and failure (defined as an inadequate improvement in depressive symptoms) with two of the following generic antidepressants is required: SNRIs, SSRIs, mirtazapine, or bupropion.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MATULANE

Products Affected

- MATULANE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

MEKINIST

Products Affected

- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

MEKINIST ORAL SOLUTION

Products Affected

- MEKINIST ORAL SOLUTION
RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Coverage requires that the patient is unable to swallow the tablet formulation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

MEKTOVI

Products Affected

- MEKTOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Patient must have documentation of BRAF V600 mutation status
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

MERCAPTOPURINE

Products Affected

- *mercaptopurine oral suspension*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have current documentation to support an inability to use generic mercaptopurine tablet.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MIFEPRISTONE

Products Affected

- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Must be prescribed by an endocrinologist.
Coverage Duration	One year.
Other Criteria	For reauthorization of previously approved requests: Must provide documentation of improvement in hyperglycemia control with mifepristone.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

modafinil

Products Affected

- *modafinil oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

MODEYSO

Products Affected

- MODEYSO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

MOUNJARO

Products Affected

- MOUNJARO SUBCUTANEOUS SOLUTION
AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	FOR T2DM: Trial with two oral generic drugs (e.g., dapagliflozin, metformin, glimepiride, glimepiride, etc.).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NAYZILAM

Products Affected

- NAYZILAM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

NERLYNX

Products Affected

- NERLYNX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months total therapy
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

NEXLETOL

Products Affected

- NEXLETOL

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used along with PCSK9 inhibitors (e.g., Repatha), Juxtapid.
Required Medical Information	Must submit most recent LDL-C level. Must submit documentation of prior therapies and responses to treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Patient must meet the following: (1) Patient has tried one high-intensity statin (or if a high-intensity strength statin is not tolerated, a maximally-tolerated statin is acceptable), along with ezetimibe for at least 4 weeks and LDL-C remains greater than or equal to 70mg/dL OR (2) Patient has tried ezetimibe for at least 4 weeks with LDL-C greater than or equal to 70mg/dL and is statin intolerant defined as trying at least two different statins and experiencing statin-related symptoms on both agents.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NEXLIZET

Products Affected

- NEXLIZET

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used along with PCSK9 inhibitors (e.g., Repatha), Juxtapid.
Required Medical Information	Must submit most recent LDL-C level. Must submit documentation of prior therapies and responses to treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Patient must meet the following: (1) Patient has tried one high-intensity statin (or if a high-intensity strength statin is not tolerated, a maximally-tolerated statin is acceptable), along with ezetimibe for at least 4 weeks and LDL-C remains greater than or equal to 70mg/dL OR (2) Patient has tried ezetimibe for at least 4 weeks with LDL-C greater than or equal to 70mg/dL and is statin intolerant defined as trying at least two different statins and experiencing statin-related symptoms on both agents.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NILOTINIB

Products Affected

- *nilotinib hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

NINLARO

Products Affected

- NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

NINTEDANIB ESYLATE

Products Affected

- *nintedanib esylate*

PA Criteria	Criteria Details
Exclusion Criteria	Not covered in combination with Jascayd or pirfenidone.
Required Medical Information	High Resolution Computed Tomography (HRCT).
Age Restrictions	
Prescriber Restrictions	Prescriber is or has consulted with a specialist in the condition being treated.
Coverage Duration	1 year initial. 2 years reauth. Dosing must follow FDA-approved labeling or Part D compendia.
Other Criteria	FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) INITIAL REQUESTS: (1) Prescriber must rule out other known causes of interstitial lung disease - AND - (2) must have presence of a UIP pattern on HRCT in patients not subjected to surgical lung biopsy. FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE WITH PROGRESSIVE PHENOTYPE: (1) confirmed diagnosis by HRCT - AND - (2) Forced Vital Capacity (FVC) decline of at least 10% - OR - at least 5% with one of the following: worsening respiratory symptoms OR worsening fibrosis on imaging. FOR SScILD INITIAL COVERAGE: Confirmed diagnosis by HRCT. FOR REAUTHORIZATION OF ALL INDICATIONS: Must have documentation of improvement in condition.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

nitisinone

Products Affected

- *nitisinone*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

NIVESTYM

Products Affected

- NIVESTYM INJECTION SOLUTION
PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

NORTRIPTYLINE

Products Affected

- *nortriptyline hcl oral*

PA Criteria	Criteria Details
Exclusion Criteria	The criteria only apply to patients 65 years and older.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	Coverage requires the following: (1) Prescriber acknowledges that the benefit of therapy outweighs the potential risks for this patient and (2) Prescriber has considered therapy changes if the patient is using more than one anticholinergic drug in combination. Note: Due to safety concerns, this medication is considered potentially inappropriate in older adults, and is best avoided, prescribed at lower dose, or used with caution.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

NUBEQA

Products Affected

- NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	FOR METASTATIC DISEASE: Patient must be unable to use (such as a failure, intolerance or contraindication to) abiraterone or Xtandi. FOR NON-METASTATIC, CASTRATION RESISTANT DISEASE: Patient must be unable to use (such as a failure, intolerance or contraindication to) Xtandi.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NUCALA

Products Affected

- NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML
- NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs.
Required Medical Information	Diagnosis, concurrent therapies (CRSwNP), and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	1 year initial, 2 years reauth. Dose must align with FDA label or Part D compendia.

PA Criteria	Criteria Details
Other Criteria	ASTHMA INITIAL COVERAGE: (1) Use of an ICS/LABA inhaler as prescribed in the past 6 months with inadequate control of condition, AND (2) Blood eosinophil level at least 150 cells per microliter in the past 12 months. CHRONIC RHINOSINUSITIS WITH NASAL POLYP (CRSwNP) INITIAL COVERAGE: (1) Chronic disease defined as 2 or more of the following symptoms for at least 12 weeks despite management (e.g., intranasal steroids, etc.): nasal congestion, obstruction, or blockage, nasal drainage, facial pain/pressure, or reduction in smell, AND (2) trial of an intranasal steroid with inadequate response, AND (3) Concurrent use of Nucala and an intranasal steroid. COPD INITIAL COVERAGE: (1) Blood eosinophil level at least 150 cells per microliter within the past 12 months, AND (2) Trial and failure of a LAMA, LABA, and ICS inhaled regimen used together (also called triple therapy) and as prescribed with failure defined as 2 or more COPD exacerbations in the past 12 months or 1 COPD hospitalization in the past 12 months. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) INITIAL COVERAGE: Clinically documented history of EGPA for at least 6 months. HYPEREOSINOPHILIC SYNDROME (HES) INITIAL COVERAGE: (1) Clinically documented history of HES for at least 6 months, AND (2) blood eosinophil count of at least 1,000 cells per microliter, AND (3) at least 2 HES flares in the past year defined as worsening HES symptoms or blood eosinophil counts requiring escalation in therapy. REAUTHORIZATION FOR ALL INDICATIONS: Documentation of clinical benefit compared to baseline (prior to Nucala) - and - for CRSwNP only - continued use of Nucala with an intranasal steroid.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NULIBRY

Products Affected

- NULIBRY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Confirmed diagnosis of MoCD Type A by genetic testing. Documentation of genetic testing results must be submitted.
Age Restrictions	
Prescriber Restrictions	Must be prescribed by, or in consultation with a physician who specializes in the treatment of inherited metabolic disorders.
Coverage Duration	Initial 1 year. Reauthorization 2 years
Other Criteria	For reauthorization requests, must also provide documentation demonstrating a beneficial response to therapy compared to pretreatment baseline in one or more of the following: neurological function, gross motor function, and/or developmental milestones.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

NUPLAZID

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

NURTEC

Products Affected

- NURTEC

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other CGRP antagonist therapy.
Required Medical Information	FOR EPISODIC MIGRAINE PREVENTION INITIAL REQUESTS: Must have at least 4 but less than 15 migraine headache days per month. FOR ACUTE MIGRAINE INITIAL REQUESTS: Unless contraindicated per the FDA label, must try and fail (defined as an intolerance or inability to improve symptoms) one generic triptan medication (e.g., sumatriptan, rizatriptan, etc.).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial: 1 year. Reauth: 1 year. Dosing must align with FDA labeling.
Other Criteria	FOR EPISODIC MIGRAINE PREVENTION REAUTHORIZATION: (1) Must have at least 4 but less than 15 migraine headache days per month, AND (2) Must provide documentation of a decrease in migraine days per month with use of Nurtec ODT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ODOMZO

Products Affected

- ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

OFEV

Products Affected

- OFEV

PA Criteria	Criteria Details
Exclusion Criteria	Not covered in combination with Jascayd or pirfenidone.
Required Medical Information	High Resolution Computed Tomography (HRCT) and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is or has consulted with a specialist in the condition being treated.
Coverage Duration	One year initial and reauth. Dosing must follow FDA-approved labeling.
Other Criteria	FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) INITIAL REQUESTS: (1) Prescriber must rule out other known causes of interstitial lung disease - AND - (2) must have presence of a UIP pattern on HRCT in patients not subjected to surgical lung biopsy - AND - (3) documented inability to use generic nintedanib. FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE WITH PROGRESSIVE PHENOTYPE: (1) confirmed diagnosis by HRCT - AND - (2) Forced Vital Capacity (FVC) decline of at least 10% - OR - at least 5% with one of the following: worsening respiratory symptoms OR worsening fibrosis on imaging - AND - (3) documented inability to use generic nintedanib. FOR SScILD INITIAL COVERAGE: (1) Confirmed diagnosis by HRCT - AND - (2) documented inability to use generic nintedanib. FOR REAUTHORIZATION OF ALL INDICATIONS: Must have documentation of: (1) improvement in condition - AND - (2) documented inability to use generic nintedanib.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

OGSIVEO

Products Affected

- OGSIVEO ORAL TABLET 100 MG, 150 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

OJEMDA

Products Affected

- OJEMDA ORAL SUSPENSION RECONSTITUTED
- OJEMDA ORAL TABLET 100 MG, 100 MG (16 PACK), 100 MG (24 PACK)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For oral suspension, coverage requires that patient is unable to swallow the tablet formulation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year. Limited to 1 box per 28 days, based on requested strength.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

OJJAARA

Products Affected

- *ojjaara*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Criteria will be applied consistent with current NCCN guidance.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ONUREG

Products Affected

- ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

OPIPZA

Products Affected

- OPIPZA ORAL FILM 10 MG, 2 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	Must have documentation of the following: (1) a current inability to swallow oral tablets, AND (2) trial and failure of two of the following generic drugs (failure does not include difficulty swallowing since the alternatives include dosage forms that can be used for patients with difficulty swallowing): aripiprazole, aripiprazole ODT, olanzapine, olanzapine ODT, quetiapine, risperidone, risperidone ODT, ziprasidone, or lurasidone.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ORENITRAM

Products Affected

- ORENITRAM
- ORENITRAM MONTH 1
- ORENITRAM MONTH 2
- ORENITRAM MONTH 3

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	FOR PULMONARY ARTERIAL HYPERTENSION (PAH): Documentation that the patient has pulmonary arterial hypertension (WHO Group 1) confirmed by right heart catheterization must be provided.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ORGOVYX

Products Affected

- ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as an intolerance or inadequate response) with Firmagon (degarelix).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	Yes
Prerequisite Therapy Required	Yes

ORKAMBI

Products Affected

- ORKAMBI ORAL PACKET
- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Patient must have laboratory confirmation of homozygous F508del mutation in the cystic fibrosis transmembrane regulator (CFTR) gene
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ORSERDU

Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Medical records supporting that the use of Orserdu follows current NCCN recommendations must be provided.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Use of Orserdu must follow current NCCN recommendations.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

OTEZLA

Products Affected

- OTEZLA ORAL TABLET
- OTEZLA ORAL TABLET THERAPY PACK
- OTEZLA XR
- OTEZLA/OTEZLA XR INITIATION PK

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	FOR MODERATE TO SEVERE PSORIASIS: Trial of a traditional DMARD (e.g., methotrexate, cyclosporine, acitretin) with inadequate response. The step therapy does not apply for MILD psoriasis. FOR ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE: Trial of colchicine with inadequate response.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OTULFI

Products Affected

- OTULFI SUBCUTANEOUS SOLUTION
- OTULFI SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 45 MG/0.5ML, 90
 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	FOR PSORIASIS: Trial of a traditional DMARD (e.g., methotrexate, cyclosporine, acitretin) with inadequate response.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OZEMPIC

Products Affected

- OZEMPIC SOLUTION PEN-INJECTOR 4 MG/3ML
- OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML
- OZEMPIC (2 MG/DOSE)
- OZEMPIC (1 MG/DOSE) SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	FOR T2DM: Trial with two oral generic drugs (e.g., dapagliflozin, metformin, glimepiride, glimepiride, etc.).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PANRETIN

Products Affected

- PANRETIN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Must first try and fail (defined as an intolerance or inability to improve the condition) with imiquimod 5% cream.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PAROXETINE

Products Affected

- *paroxetine hcl*

PA Criteria	Criteria Details
Exclusion Criteria	The criteria only apply to patients 65 years and older.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	Coverage requires the following: (1) Prescriber acknowledges that the benefit of therapy outweighs the potential risks for this patient, and (2) Prescriber has considered therapy changes if the patient is using more than one anticholinergic drug in combination. Note: Due to safety concerns, this medication is considered potentially inappropriate in older adults, and is best avoided, prescribed at lower dose, or used with caution.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

PAZOPANIB

Products Affected

- *pazopanib hcl oral tablet 200 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

PEMAZYRE

Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

penicillamine

Products Affected

- *penicillamine oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	For cystinuria, documentation that treatment with conservative measures (e.g. high fluid intake, sodium and protein restriction, urinary alkalization) were ineffective, not tolerated, or contraindicated. Quantity limited to dosage as supported by the FDA-approved label.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

PERAMPANEL

Products Affected

- *perampanel oral suspension*
- *perampanel oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as inadequate seizure control) with at least 2 generic anticonvulsants for the condition.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PHENOBARBITAL

Products Affected

- *phenobarbital oral elixir*
- *phenobarbital oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

PIQRAY

Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

PIRFENIDONE

Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 801 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For all indications, must have documentation of High Resolution Computed Tomography (HRCT) confirming diagnosis.
Age Restrictions	
Prescriber Restrictions	Prescriber is or has consulted with a pulmonologist.
Coverage Duration	Two years
Other Criteria	For idiopathic pulmonary fibrosis (IPF): (1) The patient's diagnosis must be confirmed by a surgical lung biopsy or by the presence of a UIP pattern on a HRCT, and (2) the prescriber must rule out other known causes of interstitial lung disease. For reauthorization requests: Documentation of improvement in condition with use of pirfenidone must be provided.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

PLEGRIDY

Products Affected

- PLEGRIDY
- PLEGRIDY STARTER PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

POMALIDOMIDE

Products Affected

- *pomalidomide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

POMALYST

Products Affected

- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation to support an inability to use generic pomalidomide.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PREVYMIS

Products Affected

- PREVYMIS ORAL PACKET
- PREVYMIS ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	200 days
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

PROLASTIN-C

Products Affected

- PROLASTIN-C INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Documentation of (1) Alpha-1-antitrypsin deficiency with a phenotype of PiZZ, PiZ (null), or Pi (null, null), or phenotypes associated with reduced serum alpha-1 antitrypsin concentrations - AND - (2) Serum AAT level less than 11 micromoles per liter (80 milligrams per deciliter if measured by radial immunodiffusion or 50 milligrams per deciliter if measure by nephelometry) - AND - (3) Symptomatic emphysema.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

protriptyline

Products Affected

- *protriptyline hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as inadequate response) with 2 of the following generic antidepressants: SSRIs, SNRIs, bupropion, mirtazapine, or trazodone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

QINLOCK

Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

RALDESY

Products Affected

- RALDESY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Coverage requires that the patient meet the following: (1) the patient is unable to swallow the generic trazodone tablet - and - (2) the patient has tried and failed (defined as depression symptoms not improving) at least one generic oral solution for depression (such as escitalopram oral solution, sertraline oral concentrate, nortriptyline oral solution).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

REDEMPLO

Products Affected

- REDEMPLO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For initial requests, documentation of the following is required: (1) Dosing aligns with FDA labeling, and (2) Confirmation of a diagnosis of familial chylomicronemia syndrome (FCS) by the following: (a) Fasting triglyceride level greater than 10 mmol/L or 880 mg/dL, AND either (b) genetic testing, or (c) a clinical diagnosis following current clinical practice guidance such as the Delphi Consensus (e.g., recurrent unexplained abdominal pain, history of pancreatitis).
Age Restrictions	Patient is 18 years of age or older
Prescriber Restrictions	Must be prescribed by or in conjunction with a specialist for the condition.
Coverage Duration	One year initial. Two years reauth.
Other Criteria	For reauthorization, documentation of the following is required: (1) Dosing aligns with FDA labeling, AND (2) Patient has had benefit from Redemplo compared to baseline (such as reduction in symptoms).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

RELISTOR

Products Affected

- RELISTOR ORAL
- RELISTOR SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Patient must not have mechanical gastrointestinal obstruction.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	Must try and fail (defined as an inadequate response or intolerance) to lactulose.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

REPATHA

Products Affected

- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Patient must meet one of the following: (1) Patient has tried a high intensity statin (i.e., atorvastatin 40 mg to 80 mg daily or rosuvastatin 20 mg to 40 mg daily) and LDL-C remains above goal, OR (2) if a high-intensity strength statin is not tolerated, the patient has tried a the maximally tolerated statin dose and LDL-C remains above goal, OR (3) Patient has tried two different statins and experienced statin-related symptoms on both agents.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RETEVMO

Products Affected

- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

REVCovi

Products Affected

- REVCovi

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must provide trough plasma ADA activity and trough dAXP levels. Must provide patient's current weight and requested dose.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year initial and reauthorization.
Other Criteria	Provider attestation that treatment will follow FDA-approved labeling with dose adjusted to maintain trough ADA activity over 30 mmol/hr/L, trough dAXP level under 0.02 mmol/L, and/or to maintain adequate immune reconstitution based on clinical assessment of the patient.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

REVUFORJ

Products Affected

- REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

REXULTI

Products Affected

- REXULTI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For agitation in Alzheimer's disease requests: (1) Must have documentation supporting a trial and failure (defined as an inadequate response) with one generic atypical antipsychotic used for at least 28 days. For all other medically-accepted indications: (1) Must have documentation supporting a trial and failure (defined above) with two generic atypical antipsychotic drugs, used for at least 28 days each.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

REZDIFFRA

Products Affected

- REZDIFFRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For initial requests, documentation supporting the following is required: (1) A diagnosis of metabolic dysfunction-associated steatohepatitis (MASH), AND (2) moderate to advanced liver fibrosis that is consistent with a fibrosis stage of F2 or F3 confirmed by biopsy or non-invasive tests (NITs), AND (3) current weight, AND (4) the patient is using Rezdiffra at a dose aligned with the FDA-approved labeling (i.e., 80 mg/day if weight is less than 100 kg, and 100 mg/day if weight is 100 kg or more), AND (5) Rezdiffra will be used in conjunction with diet and exercise as per its FDA labeling, AND (6) trial and failure with semaglutide.
Age Restrictions	
Prescriber Restrictions	Must be prescribed by, or in consultation, with a specialist
Coverage Duration	One year initial and reauthorization.
Other Criteria	For reauthorization, documentation supporting the following is required: (1) current ALT and/or fibrosis score supporting that the patient's liver disease has not worsened (worsening of liver disease is defined as a consistent increase in ALT or fibrosis progression assessed by biopsy or NITs), AND (2) current weight, AND (3) the patient is using Rezdiffra at a dose aligned with the FDA-approved labeling (i.e., 80 mg/day if weight is less than 100 kg, and 100 mg/day if weight is 100 kg or more), AND (4) Rezdiffra will be used in conjunction with diet and exercise as per its FDA labeling.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

REZLIDHIA

Products Affected

- REZLIDHIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

REZUROCK

Products Affected

- REZUROCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year initial and continuation.
Other Criteria	Other criteria will be applied consistent with current NCCN guidance. Reauthorization for GVHD: Must have documentation of clinical benefit.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

RINVOQ

Products Affected

- RINVOQ LQ
- RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 15 MG, 30 MG, 45 MG

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	FOR RHEUMATOID ARTHRITIS: Trial of a traditional DMARD (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) with inadequate response. FOR PSORIASIS: Trial of a traditional DMARD (e.g., methotrexate, cyclosporine, acitretin) with inadequate response. FOR ANKYLOSING SPONDYLITIS: Trial of an NSAID with inadequate response. FOR HIDRADENITIS SUPPURATIVA: Trial of one other therapy (e.g., prednisone, clindamycin) with inadequate response. FOR UVEITIS: Trial of one other therapy (e.g., intraocular or oral steroid) with inadequate response. FOR JUVENILE IDIOPATHIC ARTHRITIS: Trial of one other therapy (e.g., methotrexate, NSAIDs) with inadequate response - or - patient is starting the drug concurrently with methotrexate, sulfasalazine, or leflunomide - or - the patient has aggressive disease, as determined by the physician.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

ROMVIMZA

Products Affected

- ROMVIMZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ROZLYTREK

Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ROZLYTREK PELLET PACK

Products Affected

- ROZLYTREK ORAL PACKET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The patient has had prior trial with AND is unable to use Rozlytrek oral capsule formulation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RUBRACA

Products Affected

- RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as an intolerance or inadequate response) with Lynparza.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RUFINAMIDE

Products Affected

- *rufinamide oral suspension 40 mg/ml*
- *rufinamide oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

RYDAPT

Products Affected

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For diagnosis of acute myeloid leukemia (AML), patient must have FLT3 mutation-positive disease as detected by an FDA-approved test.
Age Restrictions	Must be age 18 or older
Prescriber Restrictions	
Coverage Duration	One year.
Other Criteria	For diagnosis of AML, patient must be using Rydapt in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

SCEMBLIX

Products Affected

- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For PH+ CML-CP with T315I mutation, documentation confirming mutation must be provided.
Age Restrictions	Must be 18 years of age or older.
Prescriber Restrictions	Must be prescribed by or in consultation with an oncologist or hematologist.
Coverage Duration	1 year. 20mg limit to 60 tabs per 30 days. 40mg limit to 240 tabs per 30 days.
Other Criteria	For PH+ CML-CP with T315I mutation, your prescriber must provide rationale supporting why Iclusig cannot be used in place of Scemblix.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

SECUADO

Products Affected

- SECUADO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as an inadequate response) with two of the following generic drugs used for at least 28 days each: aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, or lurasidone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SIGNIFOR

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Patient must be too ill for pituitary surgery or patient must have had surgery that failed to completely removed the tumor. Patient must have a documented trial with ketoconazole to reduce cortisol secretion.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SILDENAFIL CITRATE

Products Affected

- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Confirmed diagnosis of Pulmonary Arterial Hypertension (PAH), World Health Organization Group 1 by right heart catheterization and medical record documentation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

SIMLANDI

Products Affected

- SIMLANDI (1 PEN) SUBCUTANEOUS 40 MG/0.4ML
AUTO-INJECTOR KIT 80 MG/0.8ML
- SIMLANDI (2 PEN)
- SIMLANDI (2 SYRINGE) SUBCUTANEOUS
PREFILLED SYRINGE KIT 20 MG/0.2ML,

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	FOR RHEUMATOID ARTHRITIS: Trial of a traditional DMARD (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) with inadequate response. FOR PSORIASIS: Trial of a traditional DMARD (e.g., methotrexate, cyclosporine, acitretin) with inadequate response. FOR ANKYLOSING SPONDYLITIS: Trial of an NSAID with inadequate response. FOR HIDRADENITIS SUPPURATIVA: Trial of one other therapy (e.g., prednisone, clindamycin) with inadequate response. FOR UVEITIS: Trial of one other therapy (e.g., intraocular or oral steroid) with inadequate response. FOR JUVENILE IDIOPATHIC ARTHRITIS: Trial of one other therapy (e.g., methotrexate, NSAIDs) with inadequate response - or - patient is starting the drug concurrently with methotrexate, sulfasalazine, or leflunomide - or - the patient has aggressive disease, as determined by the physician.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

SIRTURO

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 weeks
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

SKYRIZI

Products Affected

- SKYRIZI PEN
 - SKYRIZI SUBCUTANEOUS SOLUTION
 - SKYRIZI SUBCUTANEOUS SOLUTION
- PREFILLED SYRINGE 150 MG/ML, 55 MG/0.37ML
CARTRIDGE 180 MG/1.2ML, 360 MG/2.4ML

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	FOR PSORIASIS: Trial of a traditional DMARD (e.g., methotrexate, cyclosporine, acitretin) with inadequate response.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SODIUM OXYBATE

Products Affected

- SODIUM OXYBATE

PA Criteria	Criteria Details
Exclusion Criteria	Patient must not be receiving sedative hypnotics with sodium oxybate. Patient must not suffer from succinic semialdehyde dehydrogenase deficiency.
Required Medical Information	Documentation of prior therapies and responses to treatment. Documentation of MSLT and polysomnography confirming diagnosis of narcolepsy.
Age Restrictions	
Prescriber Restrictions	Prescriber must be a sleep specialist or neurologist.
Coverage Duration	Two years
Other Criteria	For narcolepsy with excessive daytime sleepiness in adults: Must first try and fail (defined as an intolerance or inability to improve the condition) amphetamine salts, dextroamphetamine or methylphenidate - AND - either modafinil or armodafinil. For reauthorization requests, must provide documentation demonstrating a decrease in excessive daytime sleepiness with narcolepsy or a decrease in cataplexy episodes.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SOFOSBUVIR-VELPATASVIR

Products Affected

- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have chronic hepatitis C infection.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Duration of therapy will be applied consistent with current AASLD/IDSA.
Other Criteria	Must have documentation to support that the use of the drug is consistent with current AASLD/IDSA guidance.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

SOMAVERT

Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

SORAFENIB

Products Affected

- *sorafenib tosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

STIVARGA

Products Affected

- STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

SUBVENITE

Products Affected

- SUBVENITE ORAL SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Patient must have documentation supporting an inability to use generic lamotrigine tablet or chewable tablet AND lamotrigine orally disintegrating tablet.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

SUNITINIB MALATE

Products Affected

- *sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

SYMDEKO

Products Affected

- SYMDEKO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Patient must have laboratory confirmation of homozygous F508del mutation or have at least one tezacaftor/ivacaftor-responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Age Restrictions	Must be age 6 or older.
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

SYMPAZAN

Products Affected

- SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The patient has had prior trial with AND has a documented contraindication (e.g. dysphagia) to BOTH generic clobazam tablet AND clobazam oral suspension.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year initial and reauthorization.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SYNJARDY

Products Affected

- SYNJARDY
- SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 12.5-1000 MG, 25-1000 MG, 5-1000 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	Must have documentation that supports an inability to use (1) generic dapagliflozin (with metformin) and (2) Jardiance (with metformin) in place of Synjardy (a combination of empagliflozin and metformin).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TABRECTA

Products Affected

- TABRECTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

tadalafil 2.5mg and 5mg (Cialis)

Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Patient must have tried and failed either 6 months of finasteride or 3 months of dutasteride and must have tried and failed 28 days of alfuzosin, doxazosin, tamsulosin, or terazosin.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

tadalafil 20mg (Adcirca)

Products Affected

- *tadalafil (pah)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Confirmed diagnosis of Pulmonary Arterial Hypertension (PAH), World Health Organization Group 1 by right heart catheterization and medical record documentation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TAFINLAR

Products Affected

- TAFINLAR ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TAFINLAR TABLET FOR ORAL SUPENSION

Products Affected

- TAFINLAR ORAL TABLET SOLUBLE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Coverage requires that the patient is unable to swallow the tablet formulation.
Age Restrictions	Must be less than 18 years old.
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TAGRISO

Products Affected

- TAGRISO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TALZENNA

Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TARPEYO

Products Affected

- TARPEYO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Must be prescribed or in consultation with a specialist for the condition.
Coverage Duration	Nine months
Other Criteria	Before the drug is covered, the patient must meet all of the following requirements: (1) Diagnosis of biopsy-verified primary immunoglobulin A nephropathy, AND (2) Patient is on ACE inhibitor or ARB therapy unless there is documentation of intolerance or contraindication, AND (3) Patient is on SGLT2 inhibitor therapy unless there is documentation of intolerance or contraindication (such as an eGFR less than 25 mL/min), AND (4) Patient has tried systemic steroids such as low-dose methylprednisolone unless there is documentation of intolerance or contraindication, AND (5) Tarpeyo is not being used beyond the initial 9-month course, as per current KDIGO guidelines, AND (6) Patient is not currently receiving dialysis and has not undergone kidney transplant.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TASIMELTEON

Products Affected

- *tasimelteon*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Must be prescribed by a sleep specialist or a neurologist.
Coverage Duration	Two years
Other Criteria	Patient must be totally blind. For reauthorization: must have documented benefit from use of tasimelteon.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TAVNEOS

Products Affected

- TAVNEOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation to support the diagnosis.
Age Restrictions	Must be 18 years of age or older.
Prescriber Restrictions	Must be prescribed by or in consultation with a specialist for the condition.
Coverage Duration	Initial 6 months. Reauthorization 12 months.
Other Criteria	Tavneos must be used as an add-on to standard therapy including cyclophosphamide, rituximab, and steroids (such as methylprednisolone or prednisone) - AND - patient does not currently require dialysis. For reauthorization: Must have a reduction in the Birmingham Vasculitis Activity Score (BVAS) - AND - steroid dose.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

tazarotene cream

Products Affected

- *tazarotene external cream 0.1 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TEMAZEPAM

Products Affected

- *temazepam oral capsule 15 mg, 30 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	End of plan year.
Other Criteria	For all indications, approve if: (1) The provider has determined that taking opioids and benzodiazepines together is medically necessary for the patient, OR (2) the patient is in hospice, palliative (end-of-life) care, has cancer and/or has sickle cell disease, OR (3) the patient will not be taking an opioid or benzodiazepine concurrently, OR (4) the patient is less than 18 years old. Note: The criteria only apply to patients 18 years of age or older with concurrent use of a benzodiazepine and opioid. The use of opioids concurrently with benzodiazepines is associated with an increased risk of opioid overdose.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TEPMETKO

Products Affected

- TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TERIFLUNOMIDE

Products Affected

- *teriflunomide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TERIPARATIDE

Products Affected

- TERIPARATIDE SUBCUTANEOUS
SOLUTION PEN-INJECTOR 560
MCG/2.24ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation supporting one of the following: (1) Trial and failure, intolerance, or contraindication to alendronate, risedronate, or ibandronate - AND - zoledronic acid, OR (2) a very high risk of fracture defined as a T-score of -3.0 or less, a T-score of -2.5 or less with a fragility fracture, or a history of severe or multiple fragility fractures regardless of T-score.
Age Restrictions	
Prescriber Restrictions	Must be prescribed by endocrinologist.
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	Yes
Prerequisite Therapy Required	Yes

testosterone gel

Products Affected

- *testosterone transdermal gel 1.62 %, 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	FOR HYPOGONADISM: Documentation of the following is required: (1) Two pre-treatment serum total testosterone levels, each taken in the morning on separate days, that are less than 300 ng/dL or that are low as defined by the laboratory reference values, AND (2) Pre-treatment clinical signs or symptoms of low testosterone other than erectile dysfunction and decreased libido (such as depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

testosterone solution

Products Affected

- *testosterone transdermal solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	FOR HYPOGONADISM: Documentation of the following is required: (1) Two pre-treatment serum total testosterone levels, each taken in the morning on separate days, that are less than 300 ng/dL or that are low as defined by the laboratory reference values, AND (2) Pre-treatment clinical signs or symptoms of low testosterone other than erectile dysfunction and decreased libido (such as depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

tetrabenazine

Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with Austedo or Ingrezza.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	CYP2D6 genotype must be provided for doses greater than 50mg/day.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

THALOMID

Products Affected

- THALOMID ORAL CAPSULE 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TIBSOVO

Products Affected

- TIBSOVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Patient must have documentation of IDH1 mutation status
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TOFACITINIB

Products Affected

- *tofacitinib citrate er*
- *tofacitinib citrate oral solution*
- *tofacitinib citrate oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	FOR RHEUMATOID ARTHRITIS: Trial of a traditional DMARD (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) with inadequate response. FOR ANKYLOSING SPONDYLITIS: Trial of an NSAID with inadequate response. FOR JUVENILE IDIOPATHIC ARTHRITIS: Trial of one other therapy (e.g., methotrexate, NSAIDs) with inadequate response - or - patient is starting the drug concurrently with methotrexate, sulfasalazine, or leflunomide - or - the patient has aggressive disease, as determined by the physician.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

tolvaptan

Products Affected

- *tolvaptan (hyponatremia)*
- *tolvaptan oral tablet*
- *tolvaptan oral tablet therapy pack*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	FOR HYPONATREMIA: (1) Documentation that confirms the patient has hypervolemic or euvolemic hyponatremia defined as a serum sodium less than 125 mEq/L or less-marked hyponatremia that is symptomatic and nonresponsive to fluid restriction (including patients with SIADH or heart failure), and (2) tolvaptan is being used at a quantity of up to 60 mg per day in line with the FDA-approved labeling. FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): (1) Patient is at risk of rapidly progressing, and (2) tolvaptan is being used at a quantity of up to 120 mg per day in line with the FDA-approved labeling.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Hyponatremia: 30 days, ADPKD: 2 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TOPIRAMATE SOLUTION

Products Affected

- *topiramate oral solution 25 mg/ml*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation to support the following: (1) an inability to use generic topiramate sprinkles, and (2) trial and failure (defined as an inability to improve the condition) with one other generic anticonvulsant.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TRETINOIN CAPSULES

Products Affected

- *tretinoin oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TRIKAFTA

Products Affected

- TRIKAFTA ORAL TABLET THERAPY PACK
- TRIKAFTA ORAL THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation confirming an FDA-Approved diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

trimipramine maleate

Products Affected

- *trimipramine maleate oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as inadequate response) with 2 of the following generic antidepressants: SSRIs, SNRIs, bupropion, mirtazapine, or trazodone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TRULICITY

Products Affected

- TRULICITY SUBCUTANEOUS SOLUTION
AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	FOR T2DM: Trial with two oral generic drugs (e.g., dapagliflozin, metformin, glimepiride, glimepiride, etc.).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TRUQAP

Products Affected

- TRUQAP ORAL TABLET 200 MG
- TRUQAP ORAL TABLET THERAPY PACK 160 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TUKYSA

Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TURALIO

Products Affected

- TURALIO ORAL CAPSULE 125 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

TYENNE

Products Affected

- TYENNE SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, Janus Kinase Inhibitor (JAKis).
Required Medical Information	For systemic sclerosis- related interstitial lung disease (SScILD): High Resolution Computed Tomography (HRCT). FOR ALL OTHER INDICATIONS: Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Initial-1 yr (SScILD), 2 yr (other). Reauth-2 yr. Dose must align with FDA label or Part D compendia
Other Criteria	FOR RHEUMATOID ARTHRITIS and JUVENILE IDIOPATHIC ARTHRITIS: Trial of two of the following with inadequate response: a preferred adalimumab product, Rinvoq, or Enbrel. FOR SScILD INITIAL COVERAGE: Confirmed diagnosis by HRCT. FOR SScILD REAUTHORIZATION: Documentation of improvement in condition.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TYMLOS

Products Affected

- TYMLOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation supporting one of the following: (1) Trial and failure, intolerance, or contraindication to alendronate, risedronate, or ibandronate - AND - zoledronic acid, OR (2) a very high risk of fracture defined as a T-score of -3.0 or less, a T-score of -2.5 or less with a fragility fracture, or a history of severe or multiple fragility fractures regardless of T-score.
Age Restrictions	
Prescriber Restrictions	Must be prescribed by endocrinologist
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	Yes
Prerequisite Therapy Required	Yes

VALCHLOR

Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	For limited/localized skin involvement, must have tried topical steroids and either topical tazarotene or topical imiquimod. For generalized skin involvement, must have tried topical steroids.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VALTOCO

Products Affected

- VALTOCO 10 MG DOSE
- VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 2 X 7.5 MG/0.1ML
- VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 2 X 10 MG/0.1ML
- VALTOCO 5 MG DOSE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

VANFLYTA

Products Affected

- VANFLYTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

VELSIPITY

Products Affected

- VELSIPITY

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	FOR ULCERATIVE COLITIS: (1) Patient has tried and failed two of the following: infliximab, adalimumab, ustekinumab, tofacitinib, Skyrizi, and Rinvoq. Failed is defined as an inability to improve the condition.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VENCLEXTA

Products Affected

- VENCLEXTA
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

VEPPANU

Products Affected

- VEPPANU

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

VERQUVO

Products Affected

- VERQUVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of prior therapies and responses to treatment must be provided. Documentation of an ejection fraction less than 45% assessed within the past 12 months must be provided.
Age Restrictions	Must be at least 18 years old.
Prescriber Restrictions	Must be prescribed by, or in consultation with, a cardiologist.
Coverage Duration	Two years
Other Criteria	Patient has symptomatic worsening chronic heart failure (NYHA class 2 to 4) - AND - has been hospitalized for heart failure in the past 6 months or treated with outpatient IV diuretic therapy for heart failure in the past 3 months AND - has tried and failed (defined as an intolerance or inability to improve symptoms) maximally tolerated doses of the following medications in combination: an ACEI, ARB, or ARNi (such as enalapril or Entresto) - AND - bisoprolol, carvedilol or metoprolol ER - AND - spironolactone or other diuretic.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VERSACLOZ

Products Affected

- VERSACLOZ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	The patient has had prior trial with AND has a documented contraindication (e.g. dysphagia) to BOTH generic clozapine tablet AND generic clozapine orally disintegrating tablet (ODT).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VERZENIO

Products Affected

- VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

vigabatrin

Products Affected

- *vigabatrin*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For refractory complex partial seizures: Must have documentation supporting a trial and failure (defined as inadequate seizure control) with at least 2 other generic anticonvulsants for the condition.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

vigadrone

Products Affected

- *vigadrone*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For refractory complex partial seizures: Must have documentation supporting a trial and failure (defined as inadequate seizure control) with at least 2 other generic anticonvulsants for the condition.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VIGAFYDE

Products Affected

- VIGAFYDE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Must be 2 years of age or younger (max age 2 years).
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

VITRAKVI

Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

VONJO

Products Affected

- VONJO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Criteria will be applied consistent with current NCCN guidance.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

VORANIGO

Products Affected

- VORANIGO ORAL TABLET 10 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

voriconazole

Products Affected

- *voriconazole intravenous solution reconstituted*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

VOSEVI

Products Affected

- VOSEVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have chronic hepatitis C infection.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 weeks
Other Criteria	(1) Must be using for retreatment of hepatitis C, AND (2) must be unable to use sofosbuvir/velpatasvir, and (3) must have documentation to support that the use of the drug is consistent with current AASLD/IDSA guidance.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VOWST

Products Affected

- VOWST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of at least 2 recurrent episodes of CDI (3 or more total CDI episodes) after failure of appropriate antibiotic treatments.
Age Restrictions	Patient must be 18 years of age or older.
Prescriber Restrictions	
Coverage Duration	1 year. Limited to 1 treatment course (12 capsules over 3 days).
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

VRAYLAR

Products Affected

- VRAYLAR ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as an inadequate response) with two of the following generic drugs that have support for the requested condition and each used for at least 28 days: aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, or lurasidone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VYNDAMAX

Products Affected

- VYNDAMAX

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with TTR-lowering agents (e.g., Amvuttra, Onpattro).
Required Medical Information	INITIAL COVERAGE OF ATTR-CM: Documentation of the following: (1) New York Heart Association (NYHA) class 1 , 2, or 3 heart failure, AND (2) an echocardiogram (ECHO) or cardiac magnetic resonance (CMR) imaging demonstrating cardiac involvement (i.e., increased left ventricular wall thickness), AND (3) diagnosis confirmed by tissue biopsy, genetic testing, or radionuclide imaging (99mTc-PYP, 99mTc-DPD, or 99mTc-HMDP scan), AND (4) if the diagnosis was confirmed by radionuclide imaging, coverage also requires documentation of Grade 2 or 3 cardiac uptake.
Age Restrictions	Must be age 18 or older.
Prescriber Restrictions	
Coverage Duration	One year initial and reauthorization.
Other Criteria	Vyndamax will not be approved if the patient has primary (light-chain) amyloidosis. FOR REAUTHORIZATION OF ATTR-CM: Coverage requires documentation of a positive clinical response to Vyndamax compared to baseline (e.g., reduced cardiovascular-related hospitalizations, improved function, improved quality of life).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

WEGOVY

Products Affected

- WEGOVY ORAL
- WEGOVY SUBCUTANEOUS SOLUTION
AUTO-INJECTOR 0.25 MG/0.5ML, 0.5
MG/0.5ML, 1 MG/0.5ML, 1.7 MG/0.75ML,
2.4 MG/0.75ML

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other GLP-1 agonists or GLP-1/GIP receptor agonists.
Required Medical Information	Diagnosis, including BMI and diet and exercise plan, fibrosis stage (for MASH).
Age Restrictions	Must be 18 years or older.
Prescriber Restrictions	Must be Prescribed by or in consultation with a specialist for the condition.
Coverage Duration	One year
Other Criteria	MACE INITIAL COVERAGE: Approval requires: (1) Prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease evidenced by intermittent claudication, peripheral arterial revascularization procedure, or amputation from atherosclerotic disease, AND (2) Baseline (prior to Wegovy) BMI is 27 kg/m ² or more, AND (3) Use of Wegovy in conjunction with active participation in a reduced calorie diet AND increased physical activity, in line with the FDA-approved labeling. MACE REAUTHORIZATION: Approval requires: (1) Documented clinical benefit compared to baseline (prior to Wegovy) such as sustained weight loss, AND (2) Use of Wegovy in conjunction with active participation in a reduced calorie diet AND increased physical activity, in line with the FDA-approved labeling. MASH INITIAL COVERAGE: Approval requires: (1) No cirrhosis, AND (2) stage F2 or F3 fibrosis identified by biopsy or NIT, AND (3) Use of Wegovy in conjunction with active participation in a reduced calorie diet AND increased physical activity, in line with the FDA-approved labeling. MASH REAUTHORIZATION: Approval requires: (1) No cirrhosis, and (2) Use of Wegovy in conjunction with active participation in a reduced calorie diet AND increased physical activity, in line with the FDA-approved labeling.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

WELIREG

Products Affected

- WELIREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

WINREVAIR

Products Affected

- WINREVAIR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For initial requests, documentation of the following is required: (1) Must have a confirmed diagnosis of Pulmonary Arterial Hypertension (PAH), World Health Organization Group 1, by right heart catheterization, AND (2) Must have WHO functional class II or III symptoms, AND (3) Must have tried and failed (defined as an inability to improve the condition) of dual therapy with a phosphodiesterase inhibitor (e.g., sildenafil or tadalafil) AND an endothelin receptor antagonist (e.g., ambrisentan or bosentan), AND (4) Winrevair will be initiated as add on therapy to at least 2 other PAH agents (e.g. ERA, PDE5i, Prostaglandins).
Age Restrictions	Must be 18 years of age or older.
Prescriber Restrictions	Must be prescribed by or in consultation with a specialist for the condition.
Coverage Duration	One year initial. Two years reauthorization.
Other Criteria	For reauthorization requests: Documentation must be provided demonstrating that the patient has had a beneficial response to Winrevair compared to pretreatment baseline in one or more of the following: improvement in WHO functional class, risk status, or 6MWD.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

WYOST

Products Affected

- WYOST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

XALKORI

Products Affected

- XALKORI ORAL CAPSULE
- XALKORI ORAL CAPSULE SPRINKLE 150 MG, 20 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

XATMEP

Products Affected

- XATMEP

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Must try and fail (defined as an intolerance or inability to improve the condition) generic methotrexate.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XCOPRI

Products Affected

- XCOPRI (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 100 & 150 MG
- XCOPRI (350 MG DAILY DOSE)
- XCOPRI ORAL TABLET 100 MG, 150 MG, 200 MG, 25 MG, 50 MG
- XCOPRI ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have documentation supporting a trial and failure (defined as inadequate seizure control) with at least 2 generic anticonvulsants for the condition.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XDEMVIY

Products Affected

- XDEMVIY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Must have a diagnosis of Demodex blepharitis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

XERMELO

Products Affected

- XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Patient must be experiencing 4 or more bowel movements per day.
Age Restrictions	Must be 18 years of age or older.
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Patient must have been receiving stable doses of somatostatin analog (SSA) therapy for at least 3 months and its use has been inadequate on its own.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XIFAXAN

Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	End of plan year (all). IBS-D limited to three, 14-day treatment courses. TD limited to three days.
Other Criteria	For travelers diarrhea (TD): Coverage requires a trial and failure (defined as an intolerance or inability to improve the condition) with azithromycin. For hepatic encephalopathy: Coverage requires a trial and failure (defined above) with lactulose.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XOLAIR

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs.
Required Medical Information	Diagnosis, baseline IgE level, current weight, concurrent therapies (nasal polyps), prior therapies. Administration information to determine coverage under Part B vs Part D.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	1 year initial, 2 years reauth. Dose must align with FDA label or Part D compendia.

PA Criteria	Criteria Details
Other Criteria	ASTHMA INITIAL COVERAGE: (1) Baseline (prior to Xolair) IgE level of at least 30 IU/mL, AND (2) current weight, AND (3) baseline positive skin test or in vitro reactivity to a perennial aeroallergen, AND (4) Use of an ICS/LABA inhaler as prescribed in the past 6 months with inadequate control of condition. ASTHMA REAUTHORIZATION: (1) Documentation of clinical benefit compared to baseline, AND (2) current weight, AND (3) Baseline IgE level. FOOD ALLERGY INITIAL COVERAGE: (1) Confirmed IgE-mediated food allergy by positive in vitro test for IgE to the specified foods AND a positive skin prick test to the specified foods, AND (2) Clinical history of a significant allergic reaction to the specified foods, AND (3) Baseline (prior to Xolair) IgE level of at least 30 IU/mL, AND (4) Xolair will be used along with a food allergen-avoidant diet, AND (5) Current weight, AND (6) Patient is at least 1 year of age. FOOD ALLERGY REAUTHORIZATION: (1) Xolair will be used along with a food allergen-avoidant diet, AND (2) current weight, AND (3) baseline IgE level. CHRONIC URTICARIA (CU) INITIAL COVERAGE: (1) Urticaria occurring for more than 6 weeks, and (2) trial of an H1 antihistamine with inadequate response. CU REAUTHORIZATION: (1) Documentation of clinical benefit compared to baseline (prior to Xolair). NASAL POLYP INITIAL COVERAGE: (1) Baseline (prior to Xolair) IgE level of at least 30 IU/mL, AND (2) Current weight, AND (3) trial of an intranasal steroid with inadequate response, AND (4) Concurrent use of Xolair and an intranasal steroid. NASAL POLYP REAUTHORIZATION: (1) Documentation of clinical benefit compared to baseline, AND (2) continued use of Xolair with an intranasal steroid, AND (3) current weight, AND (4) baseline IgE level.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XOSPATA

Products Affected

- XOSPATA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

XPOVIO

Products Affected

- XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG
- XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 10 MG
- XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG, 80 MG
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

XTANDI

Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Coverage of Xtandi requires documentation supporting a trial of abiraterone acetate (generic Zytiga) with inadequate response, disease progression, or intolerance OR contraindication to the use of abiraterone acetate. Exception: For members with non-metastatic castration-resistant prostate cancer (nmCRPC), abiraterone trial does not apply.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XTRENBO

Products Affected

- XTRENBO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	One year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

YESINTEK

Products Affected

- YESINTEK SUBCUTANEOUS SOLUTION
- YESINTEK SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 45 MG/0.5ML, 90
 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	FOR PSORIASIS: Trial of a traditional DMARD (e.g., methotrexate, cyclosporine, acitretin) with inadequate response.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

YUTREPIA

Products Affected

- YUTREPIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis, chest CT (for WHO Group 3), prior therapies (for WHO Group 1), and clinical response (for reauth).
Age Restrictions	
Prescriber Restrictions	Must be prescribed by or in consultation with a specialist for the condition.
Coverage Duration	One year initial. Two years reauth.
Other Criteria	FOR PAH (WHO GROUP 1) INITIAL COVERAGE: Diagnosis confirmed by right heart catheterization, and (2) WHO/NYHA Functional Class 3 or 4 symptoms, AND (3) trial of an endothelin receptor antagonist (such as ambrisentan, bosentan) or a PDE5 inhibitor (such as tadalafil, sildenafil). FOR PH-ILD (WHO GROUP 3) INITIAL COVERAGE: Diagnosis confirmed by right heart catheterization AND (2) evidence of diffuse parenchymal lung disease (i.e., interstitial lung disease) on chest CT. FOR REAUTHORIZATION FOR ALL INDICATIONS: Documented clinical response to therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZEJULA

Products Affected

- ZEJULA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ZELBORAF

Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ZOLINZA

Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ZONISADE

Products Affected

- ZONISADE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For doses above 400 mg per day, documentation confirming need for further seizure reduction is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	Must have tried generic zonisamide capsules with inability to swallow capsule - AND - must have tried and failed (defined as an inability to improve the condition) one other generic antiseizure medication.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZTALMY

Products Affected

- ZTALMY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	(1) Must provide confirmation of CDKL5 deficiency based on genetic testing, (2) Must provide patient's current weight.
Age Restrictions	Must be 2 years of age or older.
Prescriber Restrictions	Must be prescribed by a neurologist.
Coverage Duration	Two years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ZURZUVAE

Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Confirmation of diagnosis of postpartum depression.
Age Restrictions	Must be 18 years of age or older.
Prescriber Restrictions	
Coverage Duration	One year. Limited to one treatment course per year.
Other Criteria	Must follow current ACOG recommendations which require the patient to be in the postpartum period (ie, within 12 months postpartum) for depression that has onset in the third trimester or within 4 weeks postpartum.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ZYKADIA

Products Affected

- ZYKADIA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Two years
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ZYMFENTRA

Products Affected

- ZYMFENTRA (2 PEN)
- ZYMFENTRA (2 SYRINGE)

PA Criteria	Criteria Details
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).
Required Medical Information	Diagnosis and prior therapies.
Age Restrictions	
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.
Coverage Duration	Two years. Dose must follow FDA-label or be supported in Part D compendia.
Other Criteria	FOR CROHN'S DISEASE: (1) Patient has tried and failed two of the following: infliximab (the use of the intravenous induction doses alone do not constitute a trial with failure), adalimumab, ustekinumab, Skyrizi, and Rinvoq. FOR ULCERATIVE COLITIS: (1) Patient has tried and failed two of the following: infliximab (the use of the intravenous induction doses alone do not constitute a trial with failure), adalimumab, ustekinumab, tofacitinib, Skyrizi, and Rinvoq. Failed is defined as an inability to improve the condition.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Index

ACTHAR.....	2	<i>bd pen needle nano ulf.....</i>	68
ACTHAR GEL.....	2	<i>bd pen needle nano ultrafine.....</i>	68
ACTIMMUNE.....	3	<i>bd pen needle orig ultrafine.....</i>	68
ADEMPAS.....	4	<i>bd pen needle original ulf.....</i>	68
AIMOVIG.....	5	<i>bd pen needle short ulf.....</i>	68
AKEEGA.....	6	<i>bd pen needle short ultrafine.....</i>	68
ALECENSA.....	7	BENLYSTA SUBCUTANEOUS.....	27
<i>alprazolam oral tablet.....</i>	8	BESREMI.....	28
ALUNBRIG ORAL TABLET 180 MG, 30		BESREMI PEN.....	28
MG, 90 MG.....	9	BETASERON SUBCUTANEOUS KIT.....	29
ALUNBRIG ORAL TABLET THERAPY		<i>bexarotene external.....</i>	31
PACK.....	9	<i>bexarotene oral.....</i>	30
<i>ambrisentan.....</i>	10	BILPREVDA.....	32
<i>amitriptyline hcl oral.....</i>	11	<i>bosentan oral tablet.....</i>	33
<i>aprepitant.....</i>	12	BOSULIF ORAL CAPSULE 100 MG, 50	
ARCALYST.....	13	MG.....	34
ARIKAYCE.....	14	BOSULIF ORAL TABLET 100 MG, 500	
<i>aripiprazole oral solution.....</i>	16	MG.....	34
<i>aripiprazole oral tablet dispersible.....</i>	15	<i>bosutinib oral tablet 100 mg, 400 mg, 500</i>	
<i>armodafinil.....</i>	17	<i>mg.....</i>	35
<i>asenapine maleate.....</i>	18	BRAFTOVI ORAL CAPSULE 75 MG.....	36
<i>assure id insulin safety syr 29g x 1/2" 1 ml.....</i>	68	<i>brivaracetam oral solution.....</i>	37
AUGTYRO ORAL CAPSULE 160 MG, 40		<i>brivaracetam oral tablet.....</i>	37
MG.....	19	BRUKINSA ORAL TABLET.....	38
AUSTEDO ORAL TABLET 12 MG, 6 MG,		BYSANTI.....	39
9 MG.....	20	BYSANTI TITRATION PACK A.....	39
AUSTEDO XR.....	20	BYSANTI TITRATION PACK B.....	39
AUSTEDO XR PATIENT TITRATION		BYSANTI TITRATION PACK C.....	39
ORAL TABLET EXTENDED RELEASE		CABOMETYX.....	40
THERAPY PACK 12 & 18 & 24 & 30 MG....	20	<i>calcipotriene-betameth diprop external</i>	
AUVELITY.....	21	<i>suspension.....</i>	41
AUVELITY TITRATION PACK.....	21	CALQUENCE ORAL TABLET.....	42
AVMAPKI FAKZYNJA CO-PACK.....	22	CAPLYTA.....	43
AVONEX PEN INTRAMUSCULAR AUTO-		CAPRELSA ORAL TABLET 100 MG, 300	
INJECTOR KIT.....	23	MG.....	45
AVONEX PREFILLED INTRAMUSCULAR		<i>carglumic acid oral tablet soluble.....</i>	46
PREFILLED SYRINGE KIT.....	23	CAVHANZA.....	47
AVTOZMA SUBCUTANEOUS.....	24	CAYSTON.....	48
AYVAKIT.....	25	<i>chlordiazepoxide hcl.....</i>	49
BALVERSA ORAL TABLET 3 MG, 4 MG,		<i>clobazam oral suspension 2.5 mg/ml.....</i>	50
5 MG.....	26	<i>clobazam oral tablet.....</i>	50
<i>bd autoshield duo.....</i>	68	<i>clonazepam oral tablet 0.5 mg, 1 mg, 2 mg.....</i>	51
<i>bd pen needle 29g x 12mm.....</i>	68	<i>clonazepam oral tablet dispersible 0.125</i>	
<i>bd pen needle micro ulf.....</i>	68	<i>mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg.....</i>	51
<i>bd pen needle micro ultrafine.....</i>	68	<i>clorazepate dipotassium oral tablet 15 mg,</i>	
<i>bd pen needle mini ulf.....</i>	68	<i>3.75 mg, 7.5 mg.....</i>	52
<i>bd pen needle mini ultrafine.....</i>	68	<i>clozapine oral tablet dispersible.....</i>	53
<i>bd pen needle nano 2nd gen.....</i>	68	COBENFY.....	54

COBENFY STARTER PACK.....	54	<i>eltrombopag olamine oral packet 12.5 mg,</i>	
COMETRIQ (100 MG DAILY DOSE)		<i>25 mg</i>	78
ORAL KIT 80 & 20 MG.....	55	<i>eltrombopag olamine oral tablet 12.5 mg,</i>	
COMETRIQ (140 MG DAILY DOSE)		<i>25 mg, 50 mg, 75 mg</i>	78
ORAL KIT 3 X 20 MG & 80 MG.....	55	<i>embecta autoshield duo</i>	68
COMETRIQ (60 MG DAILY DOSE).....	55	<i>embecta pen needle nano</i>	68
<i>comfort assist insulin syringe 29g x 1/2" 1</i>		<i>embecta pen needle nano 2 gen</i>	68
<i>ml</i>	68	<i>embecta pen needle ultrafine</i>	68
COPIKTRA.....	56	EMGALITY.....	80
CORTROPHIN.....	57	EMGALITY (300 MG DOSE).....	80
COSENTYX (300 MG DOSE).....	59	EMSAM.....	81
COSENTYX SENSOREADY (300 MG).....	59	ENBREL MINI.....	83
COSENTYX SUBCUTANEOUS		ENBREL SUBCUTANEOUS SOLUTION	
SOLUTION PREFILLED SYRINGE 75		<i>25 MG/0.5ML</i>	82
<i>MG/0.5ML</i>	59	ENBREL SUBCUTANEOUS SOLUTION	
COSENTYX UNOREADY.....	59	PREFILLED SYRINGE <i>25 MG/0.5ML, 50</i>	
COTELLIC.....	60	<i>MG/ML</i>	82
CRESEMBA ORAL.....	61	ENBREL SURECLICK SUBCUTANEOUS	
<i>cvs gauze sterile pad 2"x2"</i>	68	SOLUTION AUTO-INJECTOR.....	82
CYSTADROPS.....	62	ENSACOVE.....	84
CYSTARAN.....	63	ENTYVIO PEN.....	85
<i>dalfampridine er</i>	64	EPIDIOLEX.....	86
DANZITEN.....	65	ERIVEDGE.....	87
<i>dasatinib oral tablet 100 mg, 140 mg, 20</i>		ERLEADA ORAL TABLET <i>240 MG, 60</i>	
<i>mg, 50 mg, 70 mg, 80 mg</i>	66	<i>MG</i>	88
DAURISMO.....	67	<i>erlotinib hcl oral tablet 100 mg, 150 mg, 25</i>	
DIACOMIT.....	69	<i>mg</i>	89
DIAZEPAM INTENSOL.....	70	<i>eslicarbazepine acetate oral tablet 200</i>	
<i>diazepam oral solution 5 mg/5ml</i>	70	<i>mg, 400 mg, 600 mg, 800 mg</i>	90
<i>diazepam oral tablet</i>	70	EUCRISA.....	91
<i>dichlorphenamide</i>	71	EULEXIN.....	92
<i>dihydroergotamine mesylate nasal</i>	72	<i>everolimus oral tablet 10 mg, 2.5 mg, 5</i>	
<i>dimethyl fumarate oral</i>	73	<i>mg, 7.5 mg</i>	93
<i>dimethyl fumarate starter pack oral</i>		<i>everolimus oral tablet soluble</i>	93
<i>capsule delayed release therapy pack</i>	73	EXXUA.....	94
DRIZALMA SPRINKLE ORAL CAPSULE		EXXUA TITRATION PACK.....	94
DELAYED RELEASE SPRINKLE <i>20 MG,</i>		FANAPT.....	95
<i>30 MG, 60 MG</i>	74	FANAPT TITRATION PACK A.....	95
<i>droxidopa</i>	75	FANAPT TITRATION PACK B ORAL	
DUPIXENT SUBCUTANEOUS SOLUTION		TABLET.....	95
AUTO-INJECTOR <i>200 MG/1.14ML, 300</i>		FANAPT TITRATION PACK C ORAL	
<i>MG/2ML</i>	76	TABLET.....	95
DUPIXENT SUBCUTANEOUS SOLUTION		FARXIGA.....	96
PEN-INJECTOR <i>200 MG/1.14ML, 300</i>		FASENRA PEN.....	97
<i>MG/2ML</i>	76	FASENRA SUBCUTANEOUS SOLUTION	
DUPIXENT SUBCUTANEOUS SOLUTION		PREFILLED SYRINGE <i>10 MG/0.5ML, 30</i>	
PREFILLED SYRINGE <i>200 MG/1.14ML,</i>		<i>MG/ML</i>	97
<i>300 MG/2ML</i>	76	FILSPARI ORAL TABLET <i>200 MG, 400</i>	
		<i>MG</i>	98

<i> fingolimod hcl</i>	100	JARDIANCE.....	137
FINTEPLA.....	101	JAYPIRCA.....	138
FOTIVDA.....	102	JYLAMVO.....	139
FRUZAQLA ORAL CAPSULE 1 MG, 5 MG		KALYDECO.....	140
.....	103	KERENDIA.....	141
GAMUNEX-C.....	134	KISQALI (200 MG DOSE).....	143
GAVRETO.....	104	KISQALI (400 MG DOSE).....	143
<i> gefitinib</i>	105	KISQALI (600 MG DOSE).....	143
GILOTRIF.....	106	KOMZIFTI.....	144
<i> glatiramer acetate subcutaneous solution</i>		KOSELUGO.....	145
<i> prefilled syringe 20 mg/ml, 40 mg/ml</i>	107	<i> krazati</i>	146
GLATOPA SUBCUTANEOUS SOLUTION		<i> lapatinib ditosylate</i>	147
PREFILLED SYRINGE 20 MG/ML, 40		LAZCLUZE ORAL TABLET 240 MG, 80	
MG/ML.....	108	MG.....	148
<i> global alcohol prep ease</i>	68	<i> lenalidomide</i>	149
GOMEKLI.....	109	LENVIMA (10 MG DAILY DOSE).....	150
HADLIMA PUSHTOUCH		LENVIMA (12 MG DAILY DOSE).....	150
SUBCUTANEOUS SOLUTION AUTO-		LENVIMA (14 MG DAILY DOSE).....	150
INJECTOR 40 MG/0.4ML, 40 MG/0.8ML..	112	LENVIMA (18 MG DAILY DOSE).....	150
HADLIMA SUBCUTANEOUS SOLUTION		LENVIMA (20 MG DAILY DOSE).....	150
PREFILLED SYRINGE 40 MG/0.4ML, 40		LENVIMA (24 MG DAILY DOSE).....	150
MG/0.8ML.....	112	LENVIMA (4 MG DAILY DOSE).....	150
HAEGARDA.....	114	LENVIMA (8 MG DAILY DOSE).....	150
HERNEXEOS.....	115	<i> levetiracetam oral tablet disintegrating</i>	
HYRNUO.....	116	<i> soluble 250 mg, 500 mg</i>	151
IBRANCE.....	117	<i> l-glutamine oral packet</i>	152
IBTROZI.....	118	<i> lidocaine external patch 5 %</i>	153
<i> icatibant acetate subcutaneous solution</i>		LIDOCAN.....	153
<i> prefilled syringe</i>	119	LIDOCAN III.....	153
ICLUSIG.....	120	LIFYORLI (125 MG DOSE).....	154
IDHIFA.....	121	LIFYORLI (150 MG DOSE).....	154
<i> imatinib mesylate oral tablet 100 mg, 400</i>		LIVTENCITY.....	155
<i> mg</i>	122	LONSURF.....	156
IMBRUVICA ORAL CAPSULE.....	123	LORAZEPAM INTENSOL.....	157
IMBRUVICA ORAL SUSPENSION.....	123	<i> lorazepam oral tablet</i>	157
IMBRUVICA ORAL TABLET 140 MG, 280		LORBRENA.....	158
MG, 420 MG.....	123	LUMAKRAS ORAL TABLET 120 MG, 240	
<i> imkeldi</i>	124	MG, 320 MG.....	159
IMPAVIDO.....	125	LUPRON DEPOT (1-MONTH)	
INCRELEX.....	126	INTRAMUSCULAR KIT 3.75 MG.....	160
<i> infliximab</i>	127	LUPRON DEPOT (3-MONTH)	
INLURIYO.....	128	INTRAMUSCULAR KIT 11.25 MG.....	160
INLYTA.....	129	LYBALVI.....	161
INQOVI.....	130	LYNPARZA ORAL TABLET.....	162
INREBIC.....	131	LYTGOBI (12 MG DAILY DOSE).....	163
ISTURISA ORAL TABLET 1 MG, 5 MG....	132	LYTGOBI (16 MG DAILY DOSE).....	163
ITOVEBI ORAL TABLET 3 MG, 9 MG.....	133	LYTGOBI (20 MG DAILY DOSE).....	163
IWILFIN.....	135	<i> macitentan</i>	164
JAKAFI.....	136	MARPLAN.....	165

MATULANE	166	OMNITROPE SUBCUTANEOUS	
MEKINIST ORAL SOLUTION		SOLUTION CARTRIDGE	110
RECONSTITUTED	168	OMNITROPE SUBCUTANEOUS	
MEKINIST ORAL TABLET 0.5 MG, 2 MG	167	SOLUTION RECONSTITUTED	110
MEKTOVI	169	ONUREG	197
<i>mercaptopurine oral suspension</i>	170	OPIPZA ORAL FILM 10 MG, 2 MG, 5 MG	198
<i>mifepristone oral tablet 300 mg</i>	171	ORENITRAM	199
<i>modafinil oral</i>	172	ORENITRAM MONTH 1	199
MODEYSO	173	ORENITRAM MONTH 2	199
MOUNJARO SUBCUTANEOUS		ORENITRAM MONTH 3	199
SOLUTION AUTO-INJECTOR	174	ORGOVYX	200
NAYZILAM	175	ORKAMBI ORAL PACKET	201
NERLYNX	176	ORKAMBI ORAL TABLET	201
NEXLETOL	177	ORSERDU ORAL TABLET 345 MG, 86	
NEXLIZET	178	MG	202
<i>nilotinib hcl</i>	179	OTEZLA ORAL TABLET	203
NINLARO	180	OTEZLA ORAL TABLET THERAPY PACK	
<i>nintedanib esylate</i>	181		203
<i>nitisinone</i>	182	OTEZLA XR	203
NIVESTYM INJECTION SOLUTION		OTEZLA/OTEZLA XR INITIATION PK	203
PREFILLED SYRINGE	183	OTULFI SUBCUTANEOUS SOLUTION	204
NORDITROPIN FLEXPPO		OTULFI SUBCUTANEOUS SOLUTION	
SUBCUTANEOUS SOLUTION PEN-		PREFILLED SYRINGE 45 MG/0.5ML, 90	
INJECTOR 10 MG/1.5ML, 15 MG/1.5ML,		MG/ML	204
5 MG/1.5ML	110	OZEMPIC	205
<i>nortriptyline hcl oral</i>	184	OZEMPIC (0.25 OR 0.5 MG/DOSE)	
<i>novofine pen needle</i>	68	SUBCUTANEOUS SOLUTION PEN-	
<i>novofine plus pen needle</i>	68	INJECTOR 2 MG/3ML	205
NUBEQA	185	OZEMPIC (1 MG/DOSE)	
NUCALA SUBCUTANEOUS SOLUTION		SUBCUTANEOUS SOLUTION PEN-	
AUTO-INJECTOR	186	INJECTOR 4 MG/3ML	205
NUCALA SUBCUTANEOUS SOLUTION		OZEMPIC (2 MG/DOSE)	205
PREFILLED SYRINGE 100 MG/ML, 40		PANRETIN	206
MG/0.4ML	186	<i>paroxetine hcl</i>	207
NUCALA SUBCUTANEOUS SOLUTION		<i>pazopanib hcl oral tablet 200 mg, 400 mg</i>	208
RECONSTITUTED	186	PEMAZYRE	209
NULIBRY	188	<i>penicillamine oral tablet</i>	210
NUPLAZID ORAL CAPSULE	189	<i>perampanel oral suspension</i>	211
NUPLAZID ORAL TABLET 10 MG	189	<i>perampanel oral tablet</i>	211
NURTEC	190	<i>phenobarbital oral elixir</i>	212
ODOMZO	191	<i>phenobarbital oral tablet</i>	212
OFEV	192	PIQRAY (200 MG DAILY DOSE)	213
OGSIVEO ORAL TABLET 100 MG, 150		PIQRAY (250 MG DAILY DOSE)	213
MG	194	PIQRAY (300 MG DAILY DOSE)	213
OJEMDA ORAL SUSPENSION		<i>pirfenidone oral capsule</i>	214
RECONSTITUTED	195	<i>pirfenidone oral tablet 267 mg, 801 mg</i>	214
OJEMDA ORAL TABLET 100 MG, 100		PLEGRIDY	215
MG (16 PACK), 100 MG (24 PACK)	195	PLEGRIDY STARTER PACK	215
<i>ojoara</i>	196	<i>pomalidomide</i>	216

POMALYST	217	SIMLANDI (2 SYRINGE)	
<i>preferred plus insulin syringe 28g x 1/2"</i>		SUBCUTANEOUS PREFILLED SYRINGE	
<i>0.5 ml.....</i>	68	KIT 20 MG/0.2ML, 40 MG/0.4ML	246
PREVYMIS ORAL PACKET	218	SIRTURO	248
PREVYMIS ORAL TABLET	218	SKYRIZI PEN.....	249
PROLASTIN-C INTRAVENOUS		SKYRIZI SUBCUTANEOUS SOLUTION	
SOLUTION.....	219	CARTRIDGE 180 MG/1.2ML, 360	
<i>protriptyline hcl.....</i>	220	MG/2.4ML	249
QINLOCK.....	221	SKYRIZI SUBCUTANEOUS SOLUTION	
RALDESY	222	PREFILLED SYRINGE 150 MG/ML, 55	
REDEMPLO	223	MG/0.37ML	249
<i>reli-on insulin syringe 29g 0.3 ml.....</i>	68	SODIUM OXYBATE.....	250
RELISTOR ORAL	224	<i>sofosbuvir-velpatasvir.....</i>	251
RELISTOR SUBCUTANEOUS	224	SOMAVERT	252
REPATHA	225	<i>sorafenib tosylate.....</i>	253
REPATHA PUSHTRONEX SYSTEM.....	225	STIVARGA.....	254
REPATHA SURECLICK.....	225	SUBVENITE ORAL SUSPENSION.....	255
RETEVMO ORAL TABLET 120 MG, 160		<i>sunitinib malate.....</i>	256
MG, 40 MG, 80 MG	226	SYMDEKO	257
REVCovi	227	SYMPAZAN	258
REVUFORJ ORAL TABLET 110 MG, 160		SYNJARDY	259
MG, 25 MG.....	228	SYNJARDY XR ORAL TABLET	
REXULTI	229	EXTENDED RELEASE 24 HOUR 10-1000	
REZDIFFRA.....	230	MG, 12.5-1000 MG, 25-1000 MG, 5-1000	
REZLIDHIA	232	MG	259
REZUROCK.....	233	TABRECTA.....	260
RINVOQ LQ.....	234	<i>tadalafil (pah).....</i>	262
RINVOQ ORAL TABLET EXTENDED		<i>tadalafil oral tablet 2.5 mg, 5 mg.....</i>	261
RELEASE 24 HOUR 15 MG, 30 MG, 45		TAFINLAR ORAL CAPSULE.....	263
MG	234	TAFINLAR ORAL TABLET SOLUBLE	264
ROMVIMZA.....	236	TAGRISSO	265
ROZLYTREK ORAL CAPSULE 100 MG,		TALZENNA.....	266
200 MG.....	237	TARPEYO	267
ROZLYTREK ORAL PACKET	238	<i>tasimelteon.....</i>	268
RUBRACA.....	239	TAVNEOS	269
<i>rufinamide oral suspension 40 mg/ml.....</i>	240	<i>tazarotene external cream 0.1 %.....</i>	270
<i>rufinamide oral tablet.....</i>	240	<i>temazepam oral capsule 15 mg, 30 mg.....</i>	271
RYDAPT	241	TEPMETKO	272
SAJAZIR SUBCUTANEOUS SOLUTION		<i>teriflunomide.....</i>	273
PREFILLED SYRINGE	119	TERIPARATIDE SUBCUTANEOUS	
SCEMBLIX ORAL TABLET 100 MG, 20		SOLUTION PEN-INJECTOR 560	
MG, 40 MG.....	242	MCG/2.24ML	274
SECUADO	243	<i>testosterone transdermal gel 1.62 %, 12.5</i>	
SIGNIFOR.....	244	<i>mg/act (1%), 20.25 mg/1.25gm (1.62%),</i>	
<i>sildenafil citrate oral tablet 20 mg.....</i>	245	<i>20.25 mg/act (1.62%), 25 mg/2.5gm (1%),</i>	
SIMLANDI (1 PEN) SUBCUTANEOUS		<i>40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%).</i>	275
AUTO-INJECTOR KIT 80 MG/0.8ML	246	<i>testosterone transdermal solution.....</i>	276
SIMLANDI (2 PEN).....	246	<i>tetrabenazine oral tablet 12.5 mg, 25 mg..</i>	277

THALOMID ORAL CAPSULE 100 MG, 50 MG	278	VORANIGO ORAL TABLET 10 MG, 40 MG	306
TIBSOVO	279	<i>voriconazole intravenous solution reconstituted</i>	307
<i>tofacitinib citrate er</i>	280	VOSEVI	308
<i>tofacitinib citrate oral solution</i>	280	VOWST	309
<i>tofacitinib citrate oral tablet</i>	280	VRAYLAR ORAL CAPSULE	310
<i>tolvaptan (hyponatremia)</i>	281	VYNDAMAX	311
<i>tolvaptan oral tablet</i>	281	WEGOVY ORAL	312
<i>tolvaptan oral tablet therapy pack</i>	281	WEGOVY SUBCUTANEOUS SOLUTION	
<i>topiramate oral solution 25 mg/ml</i>	282	AUTO-INJECTOR 0.25 MG/0.5ML, 0.5	
<i>tretinoin oral</i>	283	MG/0.5ML, 1 MG/0.5ML, 1.7 MG/0.75ML,	
TRIDACAINE III	153	2.4 MG/0.75ML	312
TRIDACAINE XL	153	WELIREG	314
TRIKAFTA ORAL TABLET THERAPY		WINREVAIR	315
PACK	284	WYOST	316
TRIKAFTA ORAL THERAPY PACK	284	XALKORI ORAL CAPSULE	317
<i>trimipramine maleate oral</i>	285	XALKORI ORAL CAPSULE SPRINKLE	
TRULICITY SUBCUTANEOUS		150 MG, 20 MG, 50 MG	317
SOLUTION AUTO-INJECTOR	286	XATMEP	318
TRUQAP ORAL TABLET 200 MG	287	XCOPRI (250 MG DAILY DOSE) ORAL	
TRUQAP ORAL TABLET THERAPY		TABLET THERAPY PACK 100 & 150 MG	319
PACK 160 MG	287	XCOPRI (350 MG DAILY DOSE)	319
TUKYSA ORAL TABLET 150 MG, 50 MG	288	XCOPRI ORAL TABLET 100 MG, 150	
TURALIO ORAL CAPSULE 125 MG	289	MG, 200 MG, 25 MG, 50 MG	319
TYENNE SUBCUTANEOUS	290	XCOPRI ORAL TABLET THERAPY PACK	
TYMLOS	291		319
VALCHLOR	292	XDEMVY	320
VALTOCO 10 MG DOSE	293	XERMELO	321
VALTOCO 15 MG DOSE NASAL LIQUID		XIFAXAN ORAL TABLET 200 MG, 550	
THERAPY PACK 2 X 7.5 MG/0.1ML	293	MG	322
VALTOCO 20 MG DOSE NASAL LIQUID		XOLAIR	323
THERAPY PACK 2 X 10 MG/0.1ML	293	XOSPATA	325
VALTOCO 5 MG DOSE	293	XPOVIO (100 MG ONCE WEEKLY) ORAL	
VANFLYTA	294	TABLET THERAPY PACK 50 MG	326
VELSIPITY	295	XPOVIO (40 MG ONCE WEEKLY) ORAL	
VENCLEXTA	296	TABLET THERAPY PACK 10 MG	326
VENCLEXTA STARTING PACK	296	XPOVIO (40 MG TWICE WEEKLY) ORAL	
VEPPANU	297	TABLET THERAPY PACK 40 MG	326
VERQUVO	298	XPOVIO (60 MG ONCE WEEKLY) ORAL	
VERSACLOZ	299	TABLET THERAPY PACK 60 MG	326
VERZENIO	300	XPOVIO (60 MG TWICE WEEKLY)	326
<i>vigabatrin</i>	301	XPOVIO (80 MG ONCE WEEKLY) ORAL	
<i>vigadrone</i>	302	TABLET THERAPY PACK 40 MG, 80 MG	326
VIGAFYDE	303	XPOVIO (80 MG TWICE WEEKLY)	326
VITRAKVI ORAL CAPSULE 100 MG, 25		XTANDI ORAL CAPSULE	327
MG	304	XTANDI ORAL TABLET 40 MG, 80 MG	327
VITRAKVI ORAL SOLUTION	304	XTRENBO	328
VONJO	305		

YESINTEK SUBCUTANEOUS SOLUTION	329
YESINTEK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML	329
YUTREPIA	330
ZEJULA ORAL TABLET	331
ZELBORAF	332
ZOLINZA	333
ZONISADE	334
ZTALMY	335
ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG	336
ZYKADIA ORAL TABLET	337
ZYMFENTRA (2 PEN)	338
ZYMFENTRA (2 SYRINGE)	338